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ABSTRACT 
Investigation of the Tailoring Steps in Pradimicin Biosynthesis 
by 
Kandy L. Napan, Doctor of Philosophy 
Utah State University, 2016 
 
Major Professors: Jixun Zhan and Jon Y. Takemoto 
Department: Biological Engineering  
 
The actinobacteria Actinomadura hibisca synthesizes the natural products 
pradimicin A-C through a type II polyketide biosynthetic pathway. Eight tailoring enzymes 
in pradimicin biosynthesis have been investigated in this work, including PdmJ, PdmW, 
PdmN, PdmT, PdmO, PdmS, PdmQ and PdmF. PdmJ and PdmW were characterized as 
cytochrome P450 hydroxylases that catalyze the incorporation of two hydroxyl groups at 
C-5 and C-6, respectively. These enzymes worked synergistically and their co-expression 
significantly improved the efficiency of the hydroxylation steps. PdmN is an amino acid 
ligase that accepts a variety of substrates and ligates a D-alanine moiety to C-16 to form 
the corresponding derivatives. PdmS and PdmQ were functionally identified as O-
glycosyltransferases. Disruption of pdmS in the genome of A. hibisca generated a 
biosynthetic precursor without sugar moieties, which validated that PdmS is the first 
glycosyltransferase that attaches the first sugar to the 5-OH of pradimicins. In contrast, 
disruption of pdmQ led to the synthesis of pradimicin B, confirming that PdmQ was 
responsible for attaching the D-xylose moiety to the 3'-OH of the first sugar portion in 
iv 
 
pradimicins. Naturally, the first sugar moiety 4',6'-dideoxy-4'-amino-D-galactose of 
pradimicin A and B is methylated at 2'-NH. When the expression of PdmO was 
compromised, the mutant strain produced mainly pradimicin C, which contains the 4',6'-
dideoxy-4'-amino-D-galactose in its structure. This suggested that PdmO was responsible 
for the N-methylation of the amino sugar. PdmF was identified as the C-11 O-
methyltransferase. Moreover, PdmT was confirmed to be an O-methyltransferase through 
gene disruption and in vitro biochemical reactions. PdmT methylates the 7-OH to form a 
methoxy group that in a later step is removed to generate the pradimicin aglycon. 
In summary, this research has identified eight important pradimicin biosynthetic 
enzymes that are involved in various tailoring steps in pradimicin biosynthesis. Several 
new pradimicin analogues has been generated by manipulating these enzymes. Their 
enzymatic properties and collaborative actions were investigated. These results not only 
provide new insights into type II polyketide biosynthetic pathways, but also enable rational 
engineering of the pradimicin biosynthetic pathway to create new analogues for drug 
development.  
(178 pages) 
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PUBLIC ABSTRACT 
Investigation of the Tailoring Steps in Pradimicin Biosynthesis 
by 
Kandy L. Napan, Doctor of Philosophy 
Utah State University, 2016 
 
Major Professors: Jixun Zhan and Jon Y. Takemoto 
Department: Biological Engineering  
 
This research focused on the investigation of the late steps in the biosynthetic 
pathway of the novel antifungal and antiviral pradimicins A-C. Pradimicins were first 
isolated from the soil bacterium Actinomadura hibisca. These bioactive molecules are 
assembled by a type II polyketide biosynthetic pathway. Although the biosynthetic gene 
cluster of pradimicin has been identified, the functions of the biosynthetic genes and how 
they work collaboratively to form the final structures of pradimicins remain unknown. This 
research aims to functionally characterize the enzymes involved in the late steps of the 
biosynthetic route. 
The early biosynthetic steps of pradimicins have been previously investigated, and 
the enzymes required to form the core pentangular structure have been identified. This 
dissertation research characterized eight biosynthetic enzymes that further tailor the core 
structure. These enzymes include PdmJ, PdmW, PdmN, PdmT, PdmO, PdmS, PdmQ and 
PdmF. Main research approaches included gene disruption, heterologous expression, 
combinatorial biosynthesis, and in vitro biochemical studies. PdmJ and PdmW were 
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characterized as cytochrome P450 hydroxylases that catalyze the incorporation of two 
hydroxyl groups at C-5 and C-6, respectively. These enzymes worked synergistically 
during pradimicin biosynthesis. PdmN is an amino acid ligase with broad substrate 
specificity. PdmS and PdmQ were identified as the dedicated O-glycosyltransferases that 
are responsible for the introduction of the first and second sugar moieties. Three 
methyltransferases involved in pradimicin biosynthesis were also identified. PdmO is a N-
methyltransferase responsible for the methylation of the amino sugar moiety. PdmF was 
identified as the C-11 O-methyltransferase, while PdmT was confirmed to be an O-
methyltransferase that methylates the 7-OH. 
Engineered biosynthesis has shown its promise in creating chemical diversity for 
drug discovery. This research has identified eight critical biosynthetic enzymes in the 
biosynthesis of pradimicins, a group of promising antiviral and antifungal compounds. The 
results from this work provide an important knowledge and technical basis for further 
engineering of this pathway to generate new pradimicin analogues for bioactivity screening. 
 
Kandy L. Napan 
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1 CHAPTER 1 
INTRODUCTION 
1.1 Background 
1.1.1 Antibiotic producing bacteria 
Among many bacteria that produce secondary metabolites, Actinomycetales, 
produce a large variety of complex compounds synthesized by the class of enzymes 
polyketide synthases (PKSs). Studies have revealed that polyketide are a rich source of 
functional molecules, such as antibiotics of pharmaceutical application, pigments, 
insecticides, immunosuppressives, and others. Actinomycetales species grow in various 
environments and their morphological characteristics look like filamentous forms 
comparable to fungi; however, the hyphae can form a chain of spores. In this taxonomical 
class, the genus Streptomyces obtains great attention, because they are among the most 
adaptable and abundant soil microorganisms. They can synthesize a variety of bioactive 
molecules such as antibiotics, antifungals, antitumoral, antivirals, anti-hypertensives, 
immunosuppressives, and others. Streptomyces coelicolor is one of the most studied 
species in this group; it is a model system to study the synthesis, regulation, and metabolism 
of second metabolites.1 Genetics studies into antibiotic regulation have been significantly 
enable by the study of its pigmented metabolites: the red compound undecylprodigiosin 
and the blue as actinorhodin.1 
The antibiotics derived from actinomycetales began with the discoveries of 
streptothricin (streptothricin F) in 1942 and of streptomycin in 1944, as well as a larger 
movement to systematically screen for antibiotics.2 From 1983 to 1994, 60-80% of 
antibacterial and anticancer medicines were derived from natural products.3 By the 1960s, 
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about 80% of antibiotics were isolated from the genus Streptomyces and it has been 
estimated that 294,300 antimicrobial compounds present in the genus Streptomyces are 
waiting to be isolated by 2020.2  
In the same taxonomic class, the species Actinomadura hibisca, isolated from a soil 
sample of the Fiji Island, produces a red pigment that protected mice from Candida, 
Aspergillus, and Cryptococcus strains.4 A. hibisca forms a white aerial mycelium and long 
straight spore-chains when cultivated in YM solid medium (yeast extract, malt extract, and 
glucose) and ISP4 (inorganic salt starch agar). The temperature range for growing is 18 C 
- 40 C. The second metabolites or red pigments synthesized showed promising in vitro 
bioactivity against the opportunistic pathogen Candida albicans, Aspergillus, 
Cryptococcus, and Sporothrix5 and prevent the early step of HIV infection 6, 7 (Table 3). 
1.1.2 Pradimicins 
In 1988, Oki and coworkers obtained the red pigments produced by A. hibisca 
through precipitation at mildly acidic condition (pH = 5) and purified them using column 
chromatography. The structures of the components were determined by chemical 
degradation and spectral analysis and were named pradimicin A, B, and C. Their structures 
encloses a 5,6-dihydrobenzo(α)naphthacenequinone core, an amino acid (D-alanine), and 
a disaccharide moiety consisting of D-xylopyranose and 4-methylamino-4-deoxy-D-
fucopyranose in pradimicin A. The sugar moiety of pradimicin B contains only a D-
xylopyranose and in pradimicin C the second sugar is substituted by a 4-amino-4-deoxy-
D-fucopyranose. The unique bioactivity and the continuous need for antifungal and 
antiviral treatments make this group of compounds a good candidate for synthesis studies.  
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Table 1. Structures of pradimicins and their derivatives. 
 
 
Compound R1 R2 Bioactivity against 
Pradimicin A4 (1) 
 
CH3 
 
 
C. albicans, Aspergillus sp., 
and anti-HIV.8 9 
Pradimicin D9  H 
Cryptococcus neoformans and 
A. flavus.9 
Pradimicin FA-113 CH2OH 
C. neoformans and Sporothrix 
schenckii.10 
Pradimicin B (2) 4 
CH3 
 
 
Saccharomyces cerevisiae and 
C. neoformans.8 
Pradimicin FB11 CH2OH C. neoformans 
Pradimicin C (3) 4 
CH3 
 
 
Sporothrix schenckii.8 
Pradimicin E9 H 
C. neoformans and C. 
albicans.9 
Pradimicin FA-213 CH2OH 
C. neoformans and S. 
schenckii.10 
Pradimicin S11  CH3 
 
S. cerevisiae, C. albicans, C. 
neoformans, Aspergillus 
fumigatus, Trichophyton 
mentagrophytes, anti-HIV, 
and anti-influenza A (except 
pradimicin FS).11 
Pradimicin FS11 CH2OH 
BMY-28864 (7)7 CH2OH 
C. albicans and C. 
neoformans.12, 13 
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Compound R1 R2 Bioactivity against 
N,N-Dimethyl 
pradimicin E13 
H 
 
S. cerevisiae, C. albicans 
ATCC38247, and C. 
neoformans.13 
BMS-18118414 CH2OH 
 
Candida species (>10), 
Trichosporon beigelii, 
Microsporum canis, and 
Paecilomyces varioti.14, 15 
Pradimicin FL11 CH2OH 
 
C. neoformans, S. cerevisiae, 
and A. fumigatus.16 
Pradimicin L11 CH3 C. neoformans.16 
 
 
As a consequence, the exploration of other bacterial species and chemical 
modifications of pradimicins have involved a major effort by several groups in order to 
find a more water soluble pradimicin (pradimicin A ≥ 50 μM).17, 18 More than 10 analogues 
are pradimicin congeners with changes in the structure of their molecules that were 
chemically modified, extracted from other species of Actinomadura, or mutants strains 
(Table 1). The bioactivity of the analogues of pradimicin listed in Table 1 varies within 
yeast, virus, and fungi species. The antiviral activity against HIV-1 inhibited its cytopathic 
effects on various strains with an EC50 ranging from 5.2 to 5.9 µg mL-1.19 Pradimicin A 
was not toxic to cell cultures at 50 µg mL-1, highest concentration tested due to low 
solubility.6 Pradimicin S, had comparable EC50 values ranging from 5.1 to 8.9 µg mL-1.19 
The biosynthetic pathway of pradimicins has been proposed based on the deduced 
functions of the protein sequences found in the gene cluster of pradimicin. The pradimicin 
gene cluster of A. hibisca is 39 kb and, contains 28 open reading frames.20 The proteins 
5 
 
involved in the pradimicin synthesis have strong similarities with the proteins in the 
confirmed synthesis pathway of the antibiotics griseorhodin, fredericamycin, and 
rubromycin.20  
Current research has proven that pradimicins are naturally synthesized by a type II 
polyketide synthase (PKS). Like the biosynthesis of many others type II PKS, the backbone 
of pradimicin A was proposed to originate via Claisen condensation of acyl-CoA 
precursors,21 i.e., one acetyl as the starter unit and 11 malonyl Co-A as the extender units. 
The minimal PKS is made up of the enzymes PdmA, PdmB, and PdmC,22 which are 
ketosynthase (KS), chain length factor (CLF), and acyl carrier protein (ACP), respectively. 
They are responsible for formation of the linear polyketide, which later undergoes 
cyclization by PdmD between the C9-C14 and C7-C16 intramolecular aldol condensations 
in the rings A and B.23 
Further studies showed that PdmA, PdmB, PdmC, PdmD, together with PdmK, 
PdmH and PdmL must be expressed together to form the pentacyclic core. This finding 
was the first evidence that monooxygenase (PdmH) and cyclases (PdmL and PdmK) work 
synergistically to oxidize ring B, and subsequently cyclize rings C and D.23  
Additionally, PdmG is the KR responsible for the reduction of a ketone to an 
alcohol at C-6 (or C-1923,24), making possible the reaction of the three enzymes PdmH, 
PdmK, and PdmL23 to form the pentangular aromatic structure. The intermediate formed 
undergoes reduction of the hydroxyl group at C-6 with an endogenous reductase. After the 
pentacyclic core is formed, PdmF is the methyltransferase responsible for catalyzing the 
methylation of the C-11 hydroxyl in ring A. PdmN is responsible for the amidation process, 
and it can accept D-serine as well as various other substrates analogues to pradimicins.24,25  
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The two P450 enzymes in the pradimicin gene cluster, PdmJ and PdmW, were 
characterized as CYP hydroxylases. They are responsible for connecting the oxygen in the 
C5 and C6 of ring D that did not originate from the malonyl-CoA precursor.24, 25 
Interestingly, these CYP enzymes did not work efficiently when expressed separately to 
form monohydroxylated products (5, 8, 10); also PdmJ showed substrate inhibition in the 
in vitro reactions26. However, both enzymes worked efficiently when expressed at the same 
time to form a dihydroxylated product (9). The synergy between PdmJ and PdmW prevents 
substrate inhibition in the synthesis of pradimicins. 
The late pradimicin biosynthetic steps are catalyzed by two glycosyltransferases, 
PdmS and PdmQ. The first sugar moiety is introduced through PdmS, which attaches the 
first sugar, 4-deoxy-D-fucopyranose, to the aglycon; this sugar then undergoes further 
modification by most likely an aminotransferase (PdmU) that is later N-methylated by 
PdmO27 to finally synthesize 4-methylamino-4-deoxy-D-fucopyranose. Consecutively, the 
second sugar D-xylose is O-linked by PdmQ to the hydroxyl at C-3' from the previous 
sugar27. It remains unclear how the 7-OH in the C ring is removed and the 14-OH is added. 
The monooxygenases PdmV and PdmM1 might be responsible for the addition of the OH 
at C-14. Investigation of the steps in the synthesis of pradimicins has led to the production 
of a series of pradimicin analogues and intermediates (Table 2), which provides important 
information for understanding the pradimicin biosynthetic pathway. 
1.1.3 Carbohydrate binding agents 
Pradimicin A has bioactivity against systemic fungal infections,28 inhibit the entry 
of HIV-1 virions into TCD4+ cells,7, 17 and behaves as a carbohydrate-binding agent (CBA) 
in the presence of calcium. CBA comes from different natural sources for example, 
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prokaryotic organisms, sea coral, algae, fungi, plants, and animals, and their nature is 
mostly peptidic (lectins). CBAs can be classified by their carbohydrate specificity, which 
may be specific to glucose, mannose, galactose, fucose, N-acetylglucosamine, N-
acetylgalactosamine, and sialic acid.9 However, little is known about non-peptidic CBAs 
(pradimicins). Moreover, CBAs can be classified according to their size: lectins are high 
molecular weight CBA and pradimicins tend to have low molecular weight.18 The antiviral 
potency of CBAs is affected by its size: the bigger the CBAs the more variation of potency 
with different virus strains. 
Because of pradimicin’s non-peptidic nature and size, it has more advantages than 
peptidic CBA. Pradimicin does not show variation in potency; instead, it is consistently 
inhibitory against HIV-1 strains. Pradimicins can easily have contact with multiple glycan 
sites on the gp120 HIV molecule. Up to 33 molecules of pradimicin A has been estimated 
to bind a single gp120 site,6 while peptidic CBAs have reduced access due to greater steric 
interference.15 Furthermore, pradimicin A recognizes and binds selectively α-1,2-mannose 
oligomers on the N-glycans from the HIV envelope gp120, which are unusual in 
mammalian cellular glycoproteins. Since pradimicins can easily be produced, purified, and 
scaled-up29 pradimicin like-molecules have the potential to be used as therapeutics. The 
investigation for more non-peptidic CBAs must be considered. 
1.1.4 Antiviral and antifungal activity 
Simultaneously, pradimicins are potential antifungal agents (Table 1) and antiviral 
small molecules.6, 17, 28, 29, 30 This property is favorable to treat HIV patients whose immune 
system is compromised and susceptible to fungal opportunistic infections.31 
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Table 2. Pradimicin biosynthetic intermediates. 
 
 
Analogues R1 R2 R3 R4 R5 R6 
G-2A (4) OH H H OH OH H 
JX134 (5) OH OH H OH OH H 
JX137a (6) 
 
H H OH OH H 
KN92 (8) OH H OH OH OH H 
KN90 (9) OH OH OH OH OH H 
KN102 (10) 
 
H OH OH OH H 
KN87 (11) 
 
OH OH OH OH H 
Pradimicinone I (12) 
 
OH OH H OCH3 OH 
KN85 (13) 
 
OH OH OH OCH3 OH 
7-O-methyl-KN85 
(14) 
 
OH OH OCH3 OCH3 OH 
11-O-methyl-JX134 
(15) 
OH OH H OH OCH3 H 
11-O-methyl-KN92 
(16) 
OH H OH OH OCH3 H 
11-O-methyl-KN87 
(17) 
 
OH OH OH OCH3 H 
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Pradimicins target Candida, Cryptococcus, and Aspergillus species32 which are the 
cause of the most frequently diagnosed fungal infections. C. albicans frequently colonizes 
the oral cavity of immunosuppressed patients and adapts easily to hardship environments, 
eventually becoming drug resistant.32 
Once HIV has infected the bloodstream, gp120 binds the macrophage receptor 
CD4+, undergoes a conformational change in both molecules,33 and then the coreceptor 
CCR5 triggers endocytosis of the virus into the macrophage. By reverse transcription, the 
viral RNA is synthesized, forcing the cell to produce viral proteins and thus new viral 
particles are released from the cell through exocytosis. Eventually the gene that codes for 
gp120 protein is altered by mutation.34 The mutated gp120 protein binds to a different co-
receptor, CXCR-4 on the T-cell. The same processes occur resulting in new virus particle 
however, when the new viruses leave the T-cells, the viruses break the plasma membrane 
and kill the T-cell causing weakening of the immune system. The humoral immune system 
binds the free virus and virus infected cells but the immune system cannot suppress HIV 
because gp120 does not trigger an efficiently antibody response strong enough to neutralize 
the infection.35 Since gp120 in HIV-1 is approximately 50% glycan, the area of the 
envelope surface left for antibody recognition in primary viruses is restricted.36 
The mode of action of pradimicin A is based on the recognition and binding of 
mannose, on the fungal membrane and HIV-1 envelops,37, 38 in the presence of Ca2+ ions. 
Pradimicins are considered a non-peptidic lectin type C because it depends on Ca2+, similar 
to the DC-SIGN lectin that originates from humans and different from GNA and HHA 
plant lectins that do not require Ca2+ to bind to gp120.6 The strictly requirement of 
pradimicin A for Ca2+ to bind to highly glycosylated regions was demonstrated using 
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BIAcore sensor chip studies by Balzarini et al.6 In the same fashion, pradimicin A requires 
Ca2+ for its antifungal activity to form the ternary complex between two molecules of 
pradimicin A, one atom of Ca2+, and four molecules of mannopyranoside8, 19 (Figure 3). 
Balzarini hypothesized that pradimicin A and other peptidic lectins have cross-linking 
ability that creates a mesh-like structure with immobilized surface glycoproteins, 
concerning the gp120 particle and the membrane of the target cell. Thus, the prevention of 
the virus entry to the host cells might be due to the cross-linked immobilized glycans that 
lose their mobility therefore their specific conformation for correct virus-cell fusion.  
 
Figure 1. HIV-1 strain under pradimicin A pressure. Map of the deleted glycosylation 
sites in gp1206. 
The pressure that pradimicin A exerts on the HIV-1 virus eventually eliminates the 
virus from the host after constant suppression or the virus can scape drug burden by 
deletions of its glycosylation sites in gp120. Figure 1 shows the results of an escalating 
pradimicin A exposure in CEM cell cultures, 9 (red circles) from 24 glycosylation sites in 
gp120 were deleted in ten virus strains. The non-mutated sites are shown in green and one 
site (blue) was created under pradimicin A pressure.6 The deletion of the glycosylated sites 
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on its envelope left the virus susceptible to be neutralized and eliminated by the immune 
system after its glycan shield is no longer integral.36 This study also reveal the molar ratio 
of 33 molecules of pradimicin A (840 D) and one molecule of gp120, allowing a higher 
number of pradimicins interacting with the virus even after mutation of few glycosylated 
sites. In contrast, cianovirin (11,000 D)39 and HHA (50,000 D)6 are peptidic anti-HIV 
CBAs which have a stoichiometric ratio of 1:5 and 1:1.5, gp120 to CBAs, due to its 
molecular weight and steric hindrance with the carbohydrates in gp120. The small size 
gives an advantage to pradimicin A to be a more reliable drug candidate with a higher 
potential to avoid pathogen drug resistance due to its high genetic barrier.29  
Table 3. In vitro antifungal activity of pradimicin A, B, and C. 
Test organism 
MIC (µg mL-1)5  
Pradimicin 
A B C 
Candida albicans IAM 4888 3.1 0.8 3.1 
Candida albicans A9540 6.3 3.1 3.1 
Cryptococcus neoformans D49 1.6 0.8 1.6 
Cryptococcus neoformans IAM 4514 1.6 1.6 1.6 
Aspergillus fumigatus IAM 2530 1.6 3.1 1.6 
Aspergillus fumigatus IAM 2034 1.6 3.1 1.6 
Aspergillus flavus FA 21436 6.3 6.3 3.1 
Fusarium moniliforme A2284 6.3 >100 50 
Trichophyton mentagrophytes # 4329 3.1 3.1 3.1 
Sporothrix Fusarium moniliforme IFO 8158 0.8 3.1 0.8 
Petriellidium boydii IFO 8158 6.3 >100 100 
Mucor spinosus IFO 5317 >100 6.3 100 
 
 
The antifungal mode of action of pradimicins is similar to their antiviral activity.5 
Yanawaka studies on the interactions of pradimicin A with methyl α-D-mannopyranoside 
and Ca2+ ions proposed a model for the mode of action of pradimicin A. This model exposes 
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the carboxylic group of D-alanine binding to mannose in the presence of Ca2+ ions40 and 
the formation of a cavity that interacts with mannose; this cavity is made of the moieties 
of the D-alanine and the rings A, B, and C from the core of pradimicin A40, 41 (Figure 2). 
The same ternary complex was identified for pradimicin BMY-28864, which has a D-
serine as amino acid moiety and two N-methyl groups on its first sugar. Both pradimicins 
have bioactivity even though their water solubility were different, BMY-28864 is >20 mg 
mL-1 while pradimicin A is 0.02 mg mL-1 in phosphate buffer saline pH 7.2.13, 42  
Nakagawa and group also confirmed the geometry of pradimicin A bound to 
mannose by using solid-state NMR analysis (DARR technique). Their experiments 
successfully detected the particular close contact of D-alanine and ABC rings of pradimicin 
with mannans.43 Also their results indicated that the C2–C4 section of mannose is situated 
near the primary mannan binding site in pradimicin A, the C2 carbon atom is pointing 
toward the ABC rings and the C3 to the D-alanine moiety. In contrast, the C1 and C6 
carbon atoms face outward from the binding site. Because the C1 of mannan is directed 
contrary to the carboxylate group of the amino acid of pradimicin, two methyl α-D-
mannopyranosyl (12)-α-D-mannopyranoside can interact without steric interference 
(Figure 3). The 2-, 3-, and 4-hydroxyl groups of mannan are implicated in hydrogen 
bonding interactions with pradimicin A.43 It is believed that the H2 proton of mannan does 
a CH/π interaction with the ring A of pradimicin A because of the short distance of 3.03 Å. 
It’s postulated that mannan coordinates Ca2+ ions through the 4-hydroxyl group. 
Pradimicin A binds α-1,2-mannose from the surface of the cell wall of yeast and α-1,6-
linked nannans residues which are in the backbone of cell-wall.43 How pradimicin A 
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disrupt the cell membrane of yeast is still unknown, moreover, it seems that pradimicin A 
also can induce apoptosis in a mutant of S. cerevisiae that lack N-glycosylation sites.38 
 
Figure 2. Putative binding model of pradimicin A and Man-OMe by Nakagawa.43 
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1.1.5 Polyketide synthase (PKS) 
Polyketides are a class of secondary metabolites produced by bacteria, fungi, and 
plants. They are an extraordinary class of natural compounds with a broad range of 
functional and structural diversity. Many polyketide natural products possess medicinally 
important activities, such as antibacterial, anticancer, antifungal, antiparasitic, 
coccidiostats, and immunosuppressive properties (Figure 4). There are three main reasons 
that encourage the research on polyketides: (1) Many polyketides have the potential for 
drug discovery and commercial value (2). Polyketide synthases (PKSs) provide a collection 
of proteins, mechanism of actions, protein-protein interaction, and molecular recognition 
to study and develop (3). Engineering of PKSs allows the generation of novel compounds 
that are difficult to synthesize by other methods.  
 
Figure 3. Representation of the pradimicin A/Ca2+ complex by Nakagawa. Two methyl 
α-D-mannopyranosyl (12)- α-D-mannopyranoside to one molecule of pradimicin A.43 
The first descriptions of bacterial type I PKSs were in 1990,44, 45 type II PKSs in 
1984,46 and type III PKSs in 1999.47 The PKS patterns have served the scientific 
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community by providing the molecular basis to explain the complicated structural 
assembly of polyketide natural products. All the PKSs known biosynthesize polyketides 
by consecutive decarboxylative condensation of the acyl-CoA precursors, and the KS 
subunit (for type II and III PKSs) catalyzes the formation of C–C bonds or the KS domain 
for type I PKSs.48  
Type I PKSs are synthesized by bacteria and fungi. PKSs I are multifunctional 
polypeptides that are organized into modules which contain diverse catalytic domains. The 
three essential domains for chain elongation are KS, acyl transferase (AT), and ACP. Other 
domains such as ketoreductase (KR), enoyl reductase (ER), dehydratase (DH), and 
methyltransferase (MT) may be present in the PKS to form diverse polyketide structures. 
The domains can be used several times in fungal iterative type I PKSs to synthesize the 
polyketide chain. In contrast, type I PKSs from bacteria are often noniterative. In an 
iterative PKS, the KS domain can take back the growing polyketide chain after each 
condensation and terminate the polyketide biosynthesis at the proper chain size.49 LovB 
from the biosynthetic pathway of lovastatin, a famous cholesterol-lowering drug from 
Aspergillus terreus, is an example of the fungal iterative PKS.50  
In noniterative modular PKSs, each module is used once, and then the polyketide 
intermediate is carried to a downstream module for further chain elongation. The antibiotic 
erythromycin is synthesized by a bacterial noniterative type I PKS consisting of a loading 
module and six extension modules.51, 52, 53 The precursors of erythromycin A consists of 
one starter unit of propionyl-CoA and six extender units of (2S)-methylmalonyl-CoA 
(carboxylated propionyl-CoA). The erythromycin PKS or DEBS for 6-deoxyerythronolide 
B synthase is made of three proteins called DEBS 1, 2, and 3. The PKS contains a loading 
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module, six chain extension modules, and a chain terminating thioesterase (TE). The chain 
elongation modules contain a KS, an AT, and an ACP domain, and variable numbers of 
dehydratase (DH), enoyl reductase (ER), and KR. After the TE domain releases the aglycon 
6-deoxyerythronolide B, it is hydroxylated and glycosylated two times and methylated on 
a sugar moiety to synthesize the final structure of the antibiotic erythromycin A (Figure 5). 
 
Figure 4. Representative polyketide natural products. 
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Figure 5. Biosynthesis of erythromycin A through a noniterative type I PKS pathway.  
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Type II PKSs are multienzyme complexes of small, discrete enzymes with specific 
functions. This diverse group of PKSs is essentially involved in the biosynthesis of 
promising drug candidates of bacterial aromatic polyketides,54 such as oxytetracycline55 
and pradimicin.23, 25, 26 The minimal PKS of type II PKSs is composed of ketoacyl synthase 
α (KSα), ketoacyl synthase β (KSβ or CLF) and acyl ACP. The minimal PKS synthesizes 
the nascent poly-β-ketone chain to the correct length. Then the polyketide chain is exposed 
to alterations catalyzed by tailoring enzymes such as KR, cyclases (CYCs), MTs, 
glycosyltransferases (GTs), hydrolases, monooxygenases, and aminotransferases. The 
polyketide backbone is synthesized by condensation of an acetyl starter unit and multiple 
malonyl-CoA as extender units. Malonyl-CoA is also a common starter unit, as well as 
other CoA substrates, such as fatty acyl-CoAs and benzoyl-CoA. The structural diversity 
and unique biological activities of aromatic polyketides are enhanced by this common 
feature. In addition, CYCs enzymes contribute to the chemical diversity by forming 
characteristic angular, linear, or discoid aromatic ring structures. The structures are then 
modified by reduction, oxidation, methylation, and glycosylation to generate the final 
polyketide. The mentioned synthetic steps provide a wide collection of structural diversity 
to the polyketides. Tailoring steps of type II PKS of the antibiotic tetracenomycin C, 
produced by S. glaucescens, involves two oxygenation and three consecutives O-
methyltransferases reactions.56 (Figure 6)  
Type III PKSs are small dimeric proteins (40-45 kDa) that typically undergo 
iterative condensation reactions with malonyl-CoA; the numbers of condensation can go 
from one to seven.57 In spite of their simplicity, type III PKSs produce several 
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arrangements of metabolites such as pyrones, chalcones, phloroglucinols, acridones, 
resorcinolic lipids, and stilbenes.58  
 
Figure 6. Biosynthesis of tetracenomycin by a type II PKS. 
It was thought previously that type III PKSs were plant-specific, but the last few 
years have shown that bacteria and fungi also harbor type III PKSs. Five groups of bacterial 
type III PKSs have been described based on the structures of their outputs.58 The first 
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bacterial type III PKS is well exemplified by RppA from the bacterium Streptomyces 
griseus.47 It synthesizes 1,3,6,8-tetrahydroxynaphthalene (THN) from five molecules of 
malonyl-CoA, which is spontaneously oxidized to flaviolin (Figure 7). Other examples of 
type III PKSs are for resveratrol59 and curcuminoids.41 A more detailed description of the 
three types of PKS is shown in Table 4. 
1.2 Engineering Significance 
Biological engineers create, design, and develop feasible methods and strategies to 
obtain alternate and reliable therapeutics that enhance human health. With modern 
technology to sequence DNA, the genomic information stored in databases is challenging 
 
Figure 7. Biosynthesis of flaviolin by a type III PKS. 
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researchers to process it and to understand how parts of the genome works together. 
Metabolic engineering could play an important role in selecting the new genetic data, 
understanding the functions and interactions of genes, and analyzing the innate metabolic 
pathways. This is applicable especially to the genetic information that synthesizes natural 
products with promising bioactivity. Using metabolic engineering to mimic the synthesis 
of therapeutic drugs in well-known microorganisms have many applications. Also, new 
drugs based on natural products can be synthesized by changing specific and/or using 
proteins or domains with specific purposes. Pradimicins have potential antifungal and 
antiviral properties, which metabolic pathways need to be characterized in order to further 
work on the synthesis of new beneficial compounds. The impact of this study in the 
pharmaceutical industry could have significant implications. This study decoded the last 
steps in the synthesis of pradimicins and produced new intermediates that allowed us to 
better understand the pradimicin metabolic pathway. In addition, all the accomplishments 
obtained in this study could have a positive impact on society because all the efforts made 
have provided new information on potential therapeutics for current diseases.  
1.3 Research Objectives 
The central hypothesis for this research is that the pradimicin A biosynthetic 
pathway can be reconstituted and engineered in a heterologous host. The main goals of my 
doctoral dissertation research are to 1) decipher the biosynthetic pathway of pradimicin, 
with a focus on the late tailoring steps; 2) generate new pradimicin analogues using 
biosynthetic and biotransformation approaches. Specific objectives include: 
22 
 
1. Characterize the tailoring enzymes PdmJ, PdmW, PdmN, PdmS, PdmQ, PdmO, 
PdmF and PdmT, and determine their roles and interactions in the biosynthetic 
process. 
2. Find and identify the intermediates in the late pradimicin biosynthetic pathway. 
Table 4. Summary of the three types of PKSs.45, 49, 60, 61 
 
 
 
 
 
 Organization Subclasses 
Minimal 
domains/enzymes 
Type I 
PKS 
Multi-domain 
enzyme.  
Several active sites 
that catalyze several 
cycles. 
Many choices of 
monomers. 
Iterative 
mono-
modular 
Non reducing KS, AT, PT, ACP 
Partially 
reducing 
KS, AT, KR, DH, 
ACP 
Highly 
reducing 
KS, AT, KR, DH, 
ER, ACP 
Non-iterative 
multi-
modular 
cis-AT KS, AT, ACP 
trans-AT KS, ACP, AT 
Type II 
PKS 
Iterative chain 
elongation by 
monofunctional 
enzymes. 
Tailoring enzymes. 
  KSα, KSβ, ACP 
Type III 
PKS 
Simple homodimers 
of ketosynthases. 
Various reactions in 
one active site. 
Specificity of starter 
and extender units, 
length, and 
cyclization 
reactions. 
   
Ketosynthase (KS), acyltransferase (AT), product template domain (PT), acyl carrier 
protein (ACP), ketoreductase (KR), dehydratase (DH), enoylreductase (ER), 
ketosynthase (KSα), chain length factor (KSβ), discrete enzymes are in bold. 
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1.4 A Guide to the Dissertation 
This dissertation is separated into six chapters. Chapter 2, published in the journal 
of Bioorganic & Medicinal Letters in 2012, will focus on the characterization of a 
cytochrome P450 (CYP) gene, pdmJ, found in the gene cluster of pradimicin. Moreover, 
the heterologous co-expression of pdmJ with glucose 1-dehydrogenase (GDH) gene was 
studied. Chapter 3, published in ChemBioChem in 2014, presents the synergistic actions of 
three tailoring enzymes in pradimicin biosynthesis. These three enzymes involved two 
CYP enzymes, pdmJ and pdmW, and one amino acid ligase, pdmN. PdmW was 
characterized as a CYP hydroxylase and its functional role in the biosynthetic pathway was 
determined. PdmN was characterized as a flexible amino acid ligase that receives different 
amino acid donors and acceptors. Chapter 4, published in the journal of Bioorganic & 
Medicinal Letters in 2015, presents the steps in the glycosylation of pradimicin A-C as well 
as the N-methylation in one of the sugar functional groups. The genes involved in these 
concerted steps, pdmS, pdmQ, and pdmO, were functionally characterized in the 
biosynthetic pathway of pradimicin A-C. Chapter 5 describes the characterization of two 
putative O-methyltransferases in the pradimicin pathway. Finally, chapter 6 includes a 
conclusion chapter that summarizes all of our findings and gives suggestions on the 
possible research directions. 
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2 CHAPTER 2 
A KEY CYTOCHROME P450 HYDROXYLASE  
IN PRADIMICIN BIOSYNTHESIS1 
2.1 Abstract 
Pradimicins A-C (1–3) are a group of antifungal and antiviral polyketides from A. 
hibisca. The sugar moieties in pradimicins are required for their biological activities. 
Consequently, the 5-OH that is used for glycosylation plays a critical role in pradimicin 
biosynthesis. A cytochrome P450 monooxygenase gene, pdmJ, was amplified from the 
genomic DNA of A. hibisca and expressed in E. coli BL21(DE3). PdmJ introduced a 
hydroxyl group to G-2A (4) at C-5 to form JX134 (5). A D-Ala-containing pradimicin 
analogue, JX137a (6) was tested as an alternative substrate, but no product was detected 
by LC-MS, indicating that PdmJ has strict substrate specificity. Kinetic studies revealed a 
typical substrate inhibition of PdmJ activity. The optimal substrate concentration for the 
highest velocity is 115 µM under the test conditions. Moreover, the conversion rate 
of 4 to 5 was reduced by the presence of 6, likely due to competitive inhibition. 
Coexpression of PdmJ and a glucose 1-dehydrogenase in E. coli BL21(DE3) provides an 
efficient method to produce the important intermediate 5 from 4.1 
2.2 Introduction 
Pradimicins A (1), B (2), and C (3) (Table 1) are a group of 
benzo[α]naphtacenequinone natural products isolated from A. hibisca P157-2 as antifungal 
                                                 
 
1 Co-authors: Zeng, J.; Takemoto, J. Y.; and Zhan, J. 
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antibiotics.2 Other analogues such as pradimicins D and E were also isolated from 
actinomycetes.3, 4, 5, 6 The structure of 1 contains an amino acid D-Ala, two sugar moieties 
including d-xylose and 4',6'-dideoxy-4'-methylamino-d-galactose, and a 
dihydrobenzo[α]naphtacenequinone aglycon. This unique structure makes 1 an effective 
viral entry inhibitor,7, 8 and a broad-spectrum fungicide.9 The sugar moieties attached to C-
5 are found essential for the biological activities of 1. Consequently, C-5 hydroxylation is 
a key step in pradimicin biosynthesis by providing the 5-OH for the introduction of the 
4',6'-dideoxy-4'-methylamino-D-galactose moiety. Pradimicins belong to a class of natural 
products called polyketides. Similar to fatty acid biosynthesis, polyketides are assembled 
through stepwise condensations of simple carboxylic acid precursors catalyzed by enzymes 
known as PKS.10 Three types of PKSs have been identified and designated as types I, II 
and III. Pradimicins are synthesized through a type II PKS pathway and the pradimicin 
biosynthetic gene cluster from A. hibisca P157-2 has been reported.11 We have previously 
investigated the early biosynthetic steps that are involved in the formation of the 
pentangular polyphenol structure. The minimum set of enzymes required to afford the 
benzo[α]naphthacenequinone core structure includes PdmABCDHKL. Addition of PdmG 
led to the biosynthesis of a key intermediate G-2A (4).12 This intermediate is subjected to 
a series of modifications by other tailoring enzymes to afford the final structure of 1.  
2.3 Materials and Methods 
2.3.1 Primers and cloning 
A. hibisca P157-2 was cultured in YM medium for 5 days, after which the genomic 
DNA was extracted from the mycelia. The gene pdmJ (1,236 bp, GenBank ID: EF151801) 
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was cloned from the genomic DNA via PCR using Phusion high-fidelity DNA polymerase 
and a pair of primers (Table 5). The start and stop codons are bold and the introduced 
restriction enzyme sites are underlined. The PCR program used for cloning of pdmJ 
included an initial denaturation step of 5 minutes at 98°C, a 20-cycle touch-down program 
(30 s denaturation at 98°C, 40 s annealing at temperatures reduced by -0.5°C/cycle from 
75°C to 65°C, 80 s extension at 72°C), followed by a final extension of 10 minutes at 72°C. 
The PCR product was ligated into pJET1.2 between the NdeI and EcoRI sites to yield 
pZJ41. After sequencing, the gene was excised from pZJ41 by NdeI and HindIII and 
subsequently ligated into pACYCDuet-1 between the same sites, yielding pKN36 (Figure 
9).  
Table 5. Primers designed to clone pdmJ and gdh genes. 
 
 
The plasmid pET20b-gdh that carries the gene gdh (786 bp) from Bacillus subtilis 
was a gift from Prof. Jianhe Xu (East China University of Science and Technology). This 
plasmid was used as a template to clone gdh using a set of primers (Table 5).The PCR 
program included an initial denaturation step of 5 minutes at 98°C, a 20-cycle regular 
program (30 s denaturation at 98°C, 40 s annealing at 62C, 45 s extension at 72°C), 
followed by a final extension of 10 minutes at 72°C. The PCR product was ligated into the 
pJET1.2 cloning vector to yield pKN13. The gdh gene was excised from pKN13 by NdeI 
Primer Sequence  
pdmJ-F-NdeI 5'-AACATATGCCCTCCTCGAAGGATGC-3' 
pdmJ-R-EcoRI 5'-AAGAATTCCTACCAGGCGATGGGCAGCG-3' 
gdh-F-NdeI 5'-AACATATGTATCCGGATTTAAAAGG-3' 
gdh-R-XhoI 5'-AACTCGAGTTAACCGCGGCCTGCCTGGA-3' 
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and XhoI. Both gdh and pdmJ were subsequently ligated into pACYCDuet-1 between NdeI 
and XhoI as well as NcoI and HindIII, respectively, yielding pKN29 (Figure 9). 
2.3.2 Protein expression and purification 
The plasmids pKN36 and pKN29 were separately transformed into the E. coli 
BL21(DE3) competent cells using the MicroPulser electroporation apparatus (BioRad). 
The cells were then plated on LB agar containing 12.5 µg/mL chloramphenicol and 
incubated at 37C overnight. To purify PdmJ, E. coli BL21(DE3)/pKN36 was grown in 
500 mL of LB medium supplemented with 12.5 µg/mL chloramphenicol at 37ºC on a rotary 
shaker at 250 rpm until the OD600 reached 0.6. The broth was then induced by 200 µM 
isopropyl β-D-1-thiogalactopyranoside (IPTG), and the culture was maintained at 28C for 
an additional 16 h. The cells were then pelleted by centrifugation at 4,000 rpm for 10 
minutes and resuspended in the lysis buffer containing 20 mM Tris-HCl (pH 7.9), 0.5 M 
NaCl, 1 mM dithiothreitol (DTT) and 0.2 mM phenylmethylsulfonyl fluoride (PMSF). The 
cells were disrupted by sonication on ice. Cell debris was removed by centrifugation at 
20,000 rpm at 2C for 30 min. The protein was loaded onto a nickel-nitrilotriacetic acid 
(Ni-NTA) column and successively eluted with buffer A (50 mM Tris-HCl, pH 7.9, 2 mM 
EDTA, 2 mM DTT and 0.1 µM PMSF) and buffer A containing 25 mM imidazole. The 
fractions were checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), and the fraction containing PdmJ was concentrated and buffer-exchanged 
into buffer A using an Amicon® Ultra-15 Millipore centrifugal filter device. The purified 
protein was stored with 20% glycerol at -80C for enzymatic studies. 
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2.3.3 Spectroscopy characterization of the cytochrome P450  
Absorption spectra of PdmJ were recorded with a spectrophotometer within 350 -
650 nm in a quartz cuvette of 1 cm path length. 5 μM PdmJ, diluted in 50 mM buffer Tris-
HCL (pH 7.9), was added with 5 mM dithionite and then separated into 2 cuvettes. For one 
cuvette, the carbon monoxide complex of PdmJ was generated by bubbling CO gas into 
the dithionite-reduced enzyme solution (for 1 min.) at room temperature and immediately 
read in the spectrophotometer. The other cuvette was read within the same spectra and used 
as the oxidized form of PdmJ13.  
2.3.4 PdmJ kinetics  
The 100-µL reaction mixture contained 100 mM Tris-HCl buffer (pH 7.9), 10 μg 
of spinach ferredoxin, 0.05 U spinach ferredoxin-NADP reductase, 1.5 mM NADPH, 133 
μg of PdmJ, and 200 μM 4. The reaction was started by adding NADPH at 28ºC and 
quenched after 10 minutes with 50 μL of methanol. The reaction was analyzed on an 
Agilent 1200 LC/MS with a C18 Eclipse Plus column (5 μm, 4.6 × 250 mm), eluted with 
a linear gradient (10 to 90% acetonitrile in water containing 0.1% trifluoroacetic acid over 
25 min). 
2.3.5 Biotransformation 
Overnight seed cultures of the strains E. coli BL21(DE3)/pKN36, E. coli 
BL21(DE3)/pKN29, and E. coli BL21(DE3)/pACYCDuet-1 were prepared. Each culture 
was inoculated to 50 mL LB broth supplemented with 25 mg mL-1 chloramphenicol and 
induced with 0.2 mM IPTG and then maintained at 28C. After 3h of induction, the 
substrate 4 was added to each fermentation broth and cultured for an additional 30 h. The 
culture was centrifuged and LC-MS analysis of the methanol extract of the sedimented and 
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ethyl acetate extract of the supernatant fraction were recovered. E. coli 
BL21(DE3)/pACYCDuet-1 was the control strain.  
2.4 Results and Discussions 
PdmJ and PdmW are two putative cytochrome P450 (CYP) monooxygenases found 
in the pradimicin biosynthetic gene cluster. CYP enzymes are widely distributed in various 
organisms. They play important physiological roles in the oxidative metabolism of 
endogenous and exogenous compounds, and are also frequently found in natural product 
biosynthetic pathways. Through combinatorial biosynthesis approach, PdmJ and PdmW 
were characterized as C-5 hydroxylase and C-6 hydroxylase, respectively. Coexpression 
of PdmJ with PdmABCDHKL in S. coelicolor CH999 gave rise to the C-5 hydroxylated 
product of 4, JX134 (5) (Table 2). Similarly, a C-6 hydroxylated derivative of 4, JX152, 
was generated when PdmW was introduced. However, the yields of both hydroxylated 
products were low,14 which has hampered further work on other downstream tailoring 
enzymes. Moreover, no in vitro studies have been conducted to understand these key 
biosynthetic enzymes. In this study, we report the reconstitution of PdmJ in E. coli 
BL21(DE3) and biochemical characterization of this enzyme as the C-5 hydroxylase. The 
purified enzyme can efficiently convert 4 into 5 both in vitro and in vivo. 
The deduced protein product of pdmJ has 411 amino acids. BLAST analysis of the 
sequence revealed numerous CYP monooxygenases, among which PdmJ shows the highest 
homology to LlpOVI with 57% identity and 71% similarity. The sequence alignment of 
PdmJ with LlpOVI, PdmW and PikC is shown in Figure 8. LlpOVI is a putative CYP 
monooxygenase that is involved in lysolipin biosynthesis in S. tendae Tü 4042.15 PikC is a 
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CYP hydroxylase from the methymycin/pikromycin biosynthetic pathway in S. 
venezuelae,16 while PdmW is another CYP hydroxylase in the pradimicin biosynthetic 
pathway that is responsible for C-6 hydroxylation.14 As shown in Figure 8, several typical 
conserved motifs in CYP enzymes were identified (boxed) in PdmJ. Motif 1 G-X-[DEH]-
T represents an oxygen-binding site and point of access for an incoming dioxygen 
molecule.17, 18 Motif 2 E-X-X-R, which is conserved in all CYP enzymes, is also present in 
PdmJ. This motif is proposed to participate in both the redox partner interaction and heme 
binding.18 Motif 3 represents the CYP cysteine heme-iron ligand signature [FW]-[SGNH]-
X-[GD]-[F]-[RKHPT]-[P]-C-[LIVMFAP]-[GAD] as indicated in the PROSITE database 
(Accession number PS00086).19 All these features strongly suggested that PdmJ is indeed 
a CYP monooxygenase. 
 
Figure 8. Amino acid sequence alignment. PdmJ sequence aligned with three other 
actinomycete CYP monooxygenases.The identical amino acid residues are shadowed in 
grey. Three conserved regions in CYP monooxygenases are boxed 
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The gene pdmJ was cloned from the genomic DNA of the pradimicin producing 
strain and ligated into pJET1.2 to yield pZJ41. After confirming the sequence of the PCR 
product, pdmJ was ligated into pACYCDuet-1 to yield the expression plasmid pKN36. The 
plasmid was transformed into E. coli BL21(DE3) and expressed at 28C. SDS-PAGE 
analysis of the soluble and insoluble fractions of the cell lysate indicated that both fractions 
contained PdmJ. The protein was then purified from the soluble fraction by Ni-NTA 
chromatography to homogeneity. PdmJ was found in the eluent by buffer A containing 25 
mM imidazole (Figure 10). SDS-PAGE analysis showed that the His6-tagged enzyme was 
pure and had the correct size (47 kDa). The yield of PdmJ was estimated to be 17.8 mg/L 
using bicinchoninic acid (BCA) protein assay. The purified PdmJ was subjected to 
spectroscopic analyses. An absolute spectrum of 5 μM ferric PdmJ in 50 mM Tris-HCl 
buffer (pH 7.9) with 20% glycerol generated at room temperature showed Soret, α and β 
bands at 417, 570, and 535 nm, respectively. 
 
Figure 9. PdmJ and GDH expression plasmids. Maps of pKN36 (pdmJ in pACYCDuet-
1 vector) and pKN29 (pdmJ and gdh in the pACYCDuet-1 vector). 
Second-derivate analysis of the Soret peak indicated that about 90% of the iron was 
in the low spin state (Figure 11A). The CO-difference spectra20 of PdmJ (Figure 11 B) 
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showed a peak at 450 nm immediately after the addition of dithionite to the enzyme 
saturated with CO, indicating that PdmJ is a CYP enzyme. However, the P450 form is 
unstable and rapidly changes to the P420 form, as revealed by the formation of the peak at 
420 nm which increased after each reading (1-minute intervals) while the peak at 450 nm 
diminished. 
 
Figure 10. SDS-PAGE analysis of expression and purification of PdmJ. M: protein 
ladder; 1: insoluble protein; 2: soluble protein; 3: flow through; 4: elution with buffer A. 
5: elution with buffer A containing 25 mM imidazole. 
With the purified PdmJ in hand, we next tested its activity through in vitro reactions. 
In our previous in vivo study, heterologous expression of PdmJ with the enzymes 
(PdmABCDGHKL) that form 4 in S. coelicolor CH999 yielded the hydroxylated product 
5.14 This indicated that 4 is a substrate of PdmJ. Accordingly, we isolated 4 from S. 
coelicolor CH999/pJX120 (Figure 12A, trace i) and used it as the substrate in our in vitro 
reactions. LC-MS analysis of the reaction mixture showed that PdmJ had converted 4 into 
a more polar product (ca. 47.8% yield) at 19.6 minutes (Figure 12 A, trace ii). This product 
was identified as 5 by a comparison of the UV/Vis spectrum (Figure 37), molecular weight 
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(448 Da, Figure 36), and retention time with those of the authentic sample, clearly 
confirming that PdmJ is the C-5 hydroxylase, which is in agreement with the in vivo result 
previously reported.14  
 
Figure 11. Spectroscopic and enzymatic analyses of PdmJ. (A) Absolute spectrum of 
ferric PdmJ. (B) CO-difference spectra of PdmJ. (C) Substrate inhibition of PdmJ-
catalyzed C-5 hydroxylation of 4. 
To study the kinetics of PdmJ, a wide range of concentrations of 4 (32-920 μM) 
were tested in the reactions. As shown in Figure 11C, when the substrate was present at 
low concentrations, the reaction rate increased with the concentration. The reaction rate 
reached the highest level, 0.7 nmol/min, when the concentration of 4 was 115 µM. When 
more substrate was provided, the reaction rate declined. A non-Michaelis-Menten kinetics 
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curve was obtained from the experimental data (Figure 11 C), likely due to the substrate 
inhibition at the higher concentrations. It is known that 1-3 are the major secondary 
metabolites of A. hibisca P157-2. The isolation yields of 1-3 in the production medium 
were 290.9, 26.8 and 18.8 mg/l, respectively. It is proposed that the enzymes in the 
pradimicin biosynthetic pathway are controlled in such a collaborative way that the 
intermediates can be efficiently utilized by the immediate downstream enzymes. 
Consequently, the physiological concentration of the biosynthetic intermediates including 
4 in A. hibisca P157-2 is low and substrate inhibition of PdmJ in this pradimicin producing 
strain does not occur. In fact, it is normal in metabolism that the concentrations of 
intracellular intermediates are much lower than the metabolic fluxes. This explains the high 
yields of 1-3 in A. hibisca P157-2 despite the substrate inhibition of PdmJ.  
To examine the substrate specificity of PdmJ, JX137a (6) (Table 2), a D-Ala 
containing analogue of 4, was isolated from S. coelicolor CH999/pJX137 and used for the 
hydroxylation assay. 6 is highly similar to 4 except that it contains a D-Ala moiety (Figure 
36 and Figure 37). However, no obvious formation of a hydroxylated product was detected 
(Figure 12, trace iv), which indicated that PdmJ has strict substrate specificity. Our 
previous study has shown that 6 is the product of coexpression of PdmN with 
PdmABCDGHKL in S. coelicolor CH999.14 Since 6 is not an appropriate substrate of PdmJ, 
it is likely that the amino acid ligation catalyzed by PdmN is a tailoring step that occurs 
after C-5 hydroxylation. Given their similar structures, we also tested whether 6 can 
interfere with the hydroxylation of 4 by competing for the substrate binding site of PdmJ. 
In the presence of 6 at 200 μM and 400 μM, the conversion rates of 4 to 5 were reduced by 
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about 40% and 80%, respectively. This indicated that although 6 is not a substrate of PdmJ, 
it can still bind to the enzyme as a competitive inhibitor. 
 
Figure 12. HPLC analysis of C-5 hydroxylation by PdmJ at 460 nm. (A) In vitro reaction 
of PmdJ with 4 and 6. (i) Standard sample of 4. (ii) The reaction mixture of PdmJ with 
4. (iii) Standard sample of 6. (iv) The reaction mixture of PdmJ with 6. (B) In vivo 
bioconversion of 4 to 5 by engineered E. coli. (i) E. coli BL21(DE3)/ pACYCDuet-1; 
(ii) E. coli BL21(DE3)/pKN36; (iii) E. coli BL21(DE3)/pKN29 with 5 g/L glucose. 
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Although lacking the flavoprotein NADPH-CYP reductase that ubiquitously exists 
in eukaryotic cells, E. coli has been found capable of supporting the activities of 
heterologous CYPs.21 We next attempted to feed 4 to E. coli BL21(DE3)/pKN36 for its 
bioconversion to 5. The substrate was added to the fermentation broth 3 h after IPTG 
induction and then maintained at 28C for an additional 30 h. The culture was centrifuged 
and LC-MS analysis of the methanol extract of the sedimented cells showed that 4 was 
converted into 5 (ca. 7.3% yield) by the engineered strain (Figure 12 B, trace ii). In contrast, 
no product was found in the ethyl acetate extract of the supernatant fraction recovered after 
centrifugation (data not shown). No bioconversion was observed by the plasmid control 
strain E. coli BL21(DE3)/pACYCDuet-1 that lacks pdmJ (Figure 12 B, trace i).  
Glucose 1-dehydrogenase (GDH) oxidizes D-glucose into D-glucono--lactone in 
the presence of cofactor NAD+ or NADP+ to regenerate NAD(P)H. Coexpression of GDH 
with CYP enzymes significantly improves the in vivo efficiency of several CYP enzymes.22, 
23 We thus tested whether coexpression of GDH and PdmJ would improve the rate of 
bioconversion of 4 to 5. Both gdh (from Bacillus subtilis) and pdmJ were cloned into 
pACYCDuet-1 to yield pKN29 that harbors the genes in two different multiple cloning 
sites and under the control of separate T7 promoters (Figure 9). As shown in Figure 12 B 
(trace iii), coexpression did show a significant improvement of the bioconversion (ca. 67.4 % 
yield) compared to E. coli BL21(DE3)/pKN36 when glucose was supplemented at 5 g/L 
in the fermentation broth, which is likely attributed to the efficient regeneration of NADPH. 
The yield may be further improved by coexpressing a NADPH-CYP reductase with PdmJ 
and GDH.  
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2.5 Conclusions 
Pradimicins represent a novel family of medicinally important natural products 
because of their significant antifungal and antiviral activities. Understanding of the 
biosynthetic mechanism of these pentangular polyphenols will advance understanding of 
polyketide biosynthesis and provide a basis for engineering biosynthesis of “unnatural” 
natural products for new drug discovery.  
We have previously investigated the early biosynthetic steps using in vivo 
combinatorial biosynthesis approach. Given the importance of the 5-OH in pradimicin 
biosynthesis and the inefficient synthesis of 5 in the Streptomyces system, we reconstituted 
PdmJ in E. coli BL21(DE3) in this study and obtained the pure enzyme for biochemical 
characterization. Our in vitro studies revealed that PdmJ can take 4 as the substrate and 
efficiently introduce a hydroxyl group to the molecule at C-5 to form 5. This hydroxyl 
group serves as a site for the subsequent glycosylations. The enzyme has narrow substrate 
specificity, as reveled by the fact that it failed to hydroxylate the highly similar compound 
6. Interestingly, the activity of this enzyme can be inhibited by 4 (substrate inhibition) and 
6 (competitive inhibition). Future structural analysis of the enzyme may reveal valuable 
information about the substrate binding and catalytic sites of PdmJ. Although substrate 
inhibition of CYP enzymes has been previously studied in drug metabolism,24, 25 this is the 
first time that a CYP hydroxylase in a type II polyketide biosynthetic pathway was found 
to be inhibited by its substrate. In vivo bioconversion of 4 to 5 was also achieved at a high 
yield by feeding the substrate to the induced fermentation broth of the E. coli strain that 
expresses PdmJ and GDH.  
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Additionally, it should be noted that the bioconversion of 4 to 5 can be done in 2 
days, rather than 8 days that is required for S. coelicolor CH999/pJX134 to produce 5.14 
Thus, bioconversion by E. coli BL21(DE3)/pKN29 is useful for producing 5 as an 
important pradimicin biosynthetic intermediate, which can be used as a starting molecule 
for further chemical or enzymatic glycosylations to generate novel pradimicin analogues.  
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3 CHAPTER 3 
SYNERGISTIC ACTIONS OF TAILORING ENZYMES IN PRADIMICIN 
BIOSYNTHESIS2 
3.1 Abstract 
Three key tailoring enzymes in pradimicin biosynthesis: PdmJ, PdmW, and PdmN, 
were investigated for their synergistic actions. PdmW was characterized as the C-6 
hydroxylase by structural characterization of the corresponding product, 6-hydroxy-G-2A. 
The efficiencies of the C-5 and C-6 hydroxylations, catalyzed respectively by PdmJ and 
PdmW, were low when they were expressed individually with the early biosynthetic 
enzymes that form G-2A. When these two cytochrome P450 enzymes were co-expressed, 
a dihydroxylated product, 5,6-dihydroxy-G-2A, was efficiently produced, indicating that 
these two enzymes work synergistically in pradimicin biosynthesis. Heterologously 
expressed PdmN in Streptomyces coelicolor CH999 converted G-2A to JX137a by ligating 
a unit of D-alanine to the carboxyl group. PdmN has relaxed substrate specificity toward 
both amino acid donors and acceptors. Through combinatorial biosynthesis, a series of new 
pradimicin analogues were produced. 1 
3.2 Introduction 
The pradimicin family of natural products was first isolated in 1988 from the soil 
bacterium A. hibisca P157-2 (ATCC 53557).2 Pradimicin A (1) is a major product from 
                                                 
 
2 Co-authors: Zhang, S.; Morgan, W.; Anderson, T.; Takemoto, J. Y.; and Zhan, J. 
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this strain. Its structure features a benzo[α]naphthacenequinone core, a D-alanine moiety, 
and a disaccharide moiety consisting of 4',6'-dideoxy-4'-methylamino-D-galactose and D-
xylose.3 In vitro and in vivo studies indicated that 1 is a promising lead compound for 
development of antifungal and antiviral drugs.4, 5, 6 It has shown significant antifungal 
activity against many clinically important pathogens, such 
as Candida, Aspergillus, Microsporum, Penicillium, and Sporothrix.3, 5 It is also a virus 
entry inhibitor and possesses selective activities against viruses such as the human 
immunodeficiency virus (HIV).7.Recent studies on the mechanism of action 
of 1 highlighted its lectin-like property in a Ca2+-dependent manner.8, 9 The carboxyl group 
of D-alanine at C-18 and the CDE rings of 1 form the cavity that interacts with the D-
mannopyranoside found in the surface envelope of several species of yeasts and in the 
glycoprotein gp120 of HIV.10 This unique mechanism of action could help meet the 
challenges of multidrug-resistant yeast and provide the basis for new therapeutic 
approaches to prevent the entry of HIV into TCD4+ cells.7, 11 
As the only family of natural carbohydrate-binding antibiotics with nonpeptidic 
skeletons (lectin mimics), pradimicins are a promising group of drug leads. To develop 
effective anti-infective drugs, BMY-28864 (7) was previously semi-synthesized, with 
improved water solubility (>40 g L−1at pH 2) and increased bioactivities over 112 and its 
analogue, BMS-181184. However, BMY-28864 was found to increase hepatic 
transaminase level in healthy humans, leading to discontinuation of the clinical trial of this 
compound.13 New analogues of 1 with improved biological activities and safety profiles 
are thus needed for new drug development. 
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Compound 1 belongs to a large family of natural products called polyketides. It is 
assembled via a type II polyketide biosynthetic pathway. Type II polyketide biosynthetic 
pathways consist of a series of discrete enzymes that work collaboratively to synthesize 
diverse molecules, such as the broad-spectrum antibiotic oxytetracycline.14 Unlike 
modular type I polyketide synthases (PKSs) and simple type III PKSs, type II PKSs form 
multi-enzyme complexes to act as an efficient assembly line. For example, the KS and CLF 
form a heterodimer to precisely control chain elongation. Together with a dissociated ACP, 
they synthesize a linear poly-β-ketone chain of the desired length and, thus, are called 
minimal PKSs. The nascent polyketide chain is then cyclized and modified by tailoring 
enzymes to yield final products. 
Combinatorial biosynthesis is an attractive approach to generating new molecules. 
In order to rationally engineer the biosynthesis of new pradimicin analogues, it is important 
to functionally characterize the involved enzymes, understand their catalytic properties, 
and gain insights into their synergistic actions in the biosynthetic process. The biosynthetic 
gene cluster of 1 has been previously reported.15 Two ABC transporter 
genes, pdmR1 and pdmR2, were found to act as resistance genes. While overexpression of 
these genes in A. hibisca P157-2 led to elevated production of 1, their introduction into 
pradimicin-sensitive microorganisms, such as Streptomyces venezuelae, increased their 
tolerance to 1.16 
In our previous work, we functionally characterized and identified the early steps 
in the biosynthetic pathway of 1. The minimal PKS, which consists of PdmA (KS), PdmB 
(CLF), and PdmC (ACP), assembles the nascent dodecaketide backbone from 12 units of 
malonyl-CoA. This 24-carbon poly-β-ketone chain is then processed by immediate 
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tailoring enzymes including PdmD, PdmK, PdmL, PdmH, and PdmG to give rise to an 
important benzo[α]naphthacenequinone intermediate, G-2A (4) (Table 2), with an average 
yield of 48.8 ± 3.2 mg L−1 in the heterologous host Streptomyces 
coelicolor CH999.17 PdmN was characterized as an amino acid ligase that ligates a 
molecule of D-alanine to the carboxyl group at C-16.14 A new pradimicin analogue JX137a 
(6) was synthesized at 31.9 ± 3.1 mg L−1 when PdmN was co-expressed with the enzymes 
that form 4. This enzyme could also accept D-serine as the donor to yield another 
derivative, JX137s. PdmJ was characterized both in vivo and in vitro as a cytochrome P450 
(CYP450) enzyme that specifically introduces a hydroxy group at C-5. Hydroxylation 
of 4 by PdmJ yielded JX134 (5).14, 18 This hydroxy group served as a site for subsequent 
glycosylations. Given the essential roles of the D-alanine and sugar moieties in the 
biological activities of 1, it is important to understand the catalytic properties of these 
tailoring enzymes and how they work together in pradimicin biosynthesis. 
In this work, the three key tailoring enzymes, including PdmW, PdmJ, and PdmN, 
were further investigated. PdmW was determined to be the C-6 hydroxylase that acts 
synergistically with the C-5 hydroxylase, PdmJ. PdmN was discovered to possess broad 
acceptor substrate specificity, and a series of new pradimicin analogues was generated 
through combinatorial biosynthesis. 
3.3 Materials and Methods 
3.3.1 General 
1D and 2D NMR spectra were recorded on a JEOL instrument (300 MHz). ESI-
MS were acquired on an Agilent 6130 LC-MS. The extracts were analyzed on an Agilent 
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1200 HPLC instrument by using an Agilent ZORBAX SB-C18 column (5 µm, 4.6 mm × 
150 mm), eluted with a gradient of CH3CN/water (25–90%) with 0.1% formic acid over 
25 minutes at a flow rate of 1 mL min-1, followed by 100% CH3CN for 5 min. Compounds 
were purified on the same HPLC instrument. The yields of the products from three different 
colonies of the same strain were analyzed by HPLC and determined by using the standard 
curves of the purified compounds. 
3.3.2 Bacterial strain and vectors 
E. coli XL-1 Blue (Stratagene) was used for routine subcloning. S. coelicolor 
CH999 was used for the expression of pdm biosynthetic genes. A. hibisca P157-2 was 
obtained from the American Type Culture Collection (ATCC). The cloning vectors used 
in this study were pCR-Blunt (Life Technologies) and pJET1.2 (Fermentas). The pRM5 E. 
coli/Streptomyces shuttle vector was used to construct the expression plasmids. 
3.3.3 Growth media and conditions 
E. coli strains were routinely grown in lysogeny broth (LB) at 37 oC. For selection 
of correct transformants, ampicillin (100 mg mL-1) or kanamycin (50 mg mL-1) were added 
as supplements. S. coelicolor CH999 was used as the heterologous host for expression of 
the pradimicin biosynthetic enzymes. The expression plasmids were introduced into S. 
coelicolor CH999 through polyethylene glycol (PEG)-mediated protoplast transformation. 
The transformants were selected on R5 agar supplemented with 50 mgmL-1 thiostrepton. 
All of the engineered strains of S. coelicolor CH999 were cultivated on R5 agar with 
thiostrepton at 28 C for production of the polyketide compounds. 
50 
 
3.3.4 Construction of plasmids 
The genes used in this study were amplified by PCR. Specific forward and reverse 
primers were designed, based on the reported sequences, to contain compatible restriction 
enzymes such as XbaI, SpeI, and NheI. The PCR products were then ligated into a cloning 
vector for DNA sequencing. Each combination of genes was constructed by the subsequent 
addition of individual genes into a cloning vector and restriction enzyme digestions 
confirmed the correct ligation. Additionally, each group of genes was ligated into a pRM5-
derived vector. The gene cassette (pdmCGHKLJ) was excised from pKN31 by using XbaI 
and SpeI and ligated into the pRM5-derived vector pJX111 (pdmABD) between the same 
sites to yield pKN35. The pdmN gene was excised from pJX97 by using XbaI and SpeI and 
ligated into the XbaI treated pKN35 to yield pKN89. Similarly, the same insert was ligated 
into XbaI-digested pJX120 to afford pKN93. The pdmW gene was excised from pJX151 
by using XbaI and NheI and ligated into XbaI-digested pKN93 to yield pKN102. The same 
insert was ligated into XbaI-digested pJX120 to yield pKN92. When pdmW was ligated 
into XbaI-digested pKN35, pKN90 was constructed. pKN87 was generated by ligating 
pdmWCGHIKLNJ into pJX111 between XbaI and SpeI. The pdmN gene was excised from 
the pKN39 plasmid by using EcoRI and PacI and ligated into the pRM5 vector between 
the same sites to yield the plasmid pKN50. All of these plasmids were introduced into S. 
coelicolor CH999 through PEG-mediated protoplast transformation for product analysis or 
biotransformation. 
3.3.5 In vivo D-alanylation 
S. coelicolor CH999/pKN50 was cultivated in R5 broth containing 50 mg mL-1 
thiostrepton at 28 C for 4 days in a rotary shaker. This seed culture (100 mL) was 
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transferred to 10 mL of fresh R5 broth with 50 mg mL-1 thiostrepton and cultured for 4 
days before the addition of 0.5 mg of 4, 5, 8, or 9 dissolved in pure DMSO. After 10 days 
of biotransformation, the cultures were centrifuged at 3220 g for 10 min. The pelleted cells 
were extracted with methanol. This MeOH extract was combined with the supernatant and 
dried in vacuo. The samples were subjected to LC-MS analysis. 
3.3.6 Extraction and isolation of compounds 
The engineered S. coelicolor CH999 strains were grown on R5 agar with 50 mg 
mL-1 thiostrepton at 28 C for 8–10 days. Products were extracted from the cultures by 
using a mixture of ethyl acetate, MeOH, and acetic acid (89:10:1). The extracts were then 
dried under reduced pressure. The extract of 6 L of S. coelicolor CH999/pKN92 was 
subjected to Diaion HP-20 resin column chromatography, eluted with 0, 25, 50, 75, and 
100% aqueous MeOH (v/v) to yield five fractions. HPLC analysis revealed that the 75% 
fraction contained the target peak. This fraction was further separated by reversed-phase 
HPLC (Agilent Zorbax SB-C18, 5 µm, 21.2 mm × 150 mm) and eluted with 55% aqueous 
CH3CN containing 0.1% formic acid, at a flow rate of 1 mL min-1, to yield 6.0 mg of 8. 
The extract of 2 L of S. coelicolor CH999/pKN90 was subjected to Diaion HP-20 resin 
column chromatography as described above. The 50% fraction that contained the target 
peak was further separated by reversed-phase HPLC (SOPELCO C18, 5 µm, 10 mm × 150 
mm), eluted with a linear gradient of 15–95% aqueous CH3CN containing 0.1% formic 
acid, at a flow rate of 1 mL min-1, over 16 minutes to yield 8.5 mg of 9. The extract of 6 L 
of S. coelicolor CH999/pKN102 was subjected to Diaion HP-20 resin column 
chromatography as described above. The 75% fraction was further separated by reversed-
phase HPLC (Agilent Zorbax SB-C18, 5 µm, 21.2 mm × 150 mm), eluted with 37% 
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aqueous CH3CN containing 0.1% formic acid, at a flow rate of 1 mL min-1, to yield 1.0 mg 
of 10. 1H NMR data of 10 in [d6] DMSO: δ=9.02 (s, 1H; H-14), 7.12 (brs, 1H; H-12), 6.61 
(s, 1H; H-4), 6.45 (brs, 1H; H-10), 5.22 (brs, 1H; H-6), 4.20 (m, 1H; H-17), 2.97 (m, 1H; 
H-5a), 2.76 (m, 1H; H-5b), 2.23 (s, 3H; H-15), 1.27 ppm (d, J= 7.2 Hz, 3H; H-19). The 
extract of 2 L of S. coelicolor CH999/pKN87 was subjected to Diaion HP-20 resin column 
chromatography as described above. The 50% fraction was found to contain the target peak. 
This fraction was dissolved in DMSO after solvent evaporation and then subjected to a 
HW-40F chromatographic column (30 mm x 100 mm), eluted with a gradient of 
MeOH/water, to remove the non-pradimicin compounds. The 50% MeOH/water elute was 
further separated by HPLC (ZORBAX SB-C18, 5 µm, 4.6 mm × 150 mm) and eluted with 
23% aqueous CH3CN containing 0.1% formic acid, at a flow rate of 1 mL min-1, to yield 
8.1 mg of 11.  
3.3.7 Determination of the absolute configuration of 5 and 8 
In order to determine the absolute configurations of 5 at C-5 and 8 at C-6, these 
compounds were reacted with (S)- and (R)-MTPA chloride separately to afford the 
corresponding (R)- and (S)-MTPA esters 5R, 5S and 8R, 8S. Their 1H, 19F, and 1H, 1H 
COSY NMR spectra were recorded in [D5]pyridine after reacting for 24 h at room 
temperature. 
3.3.8 Antifungal assays of 4-11 
The antifungal activities of compounds 4–11 were tested against C. albicans ATCC 
MYA-2876. The inoculum was prepared by cultivating a single colony of C. albicans in 5 
mL of potato dextrose broth (PDB) supplemented with 200 mm CaCl2 at 35 C for 24 h. 
The inoculum was diluted with PDB and titrated with a hemocytometer to reach a final 
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inoculum size of 2 x 106 CFU mL-1. Stock solutions of each test compound were prepared 
in 50% aqueous DMSO with a concentration of 5 mg mL-1. The test concentrations ranged 
from 0.9 to 500 mg mL-1. Clotrimazole was dissolved in pure DMSO and used as a positive 
control.  
3.4 Results and Discussions 
3.4.1 Characterization of PdmW as the C-6 hydroxylase  
To identify the function of PdmW, we constructed plasmid pKN92 (Table 6), which 
consists of pdmW and the G-2A-forming genes, by using an E. coli/Streptomyces shuttle 
vector pRM5.19 This vector contains a ColE1 replicon for replication in E. coli and a SCP2 
replicon for Streptomyces. For comparison, a similar plasmid pKN35 was constructed 
containing the same set of genes except that pdmW was replaced by pdmJ (Table 6). These 
two plasmids were introduced into S. coelicolor CH999 by protoplast transformation, and 
correct transformants were grown on R5 agar supplemented with thiostrepton for product 
analysis.  
Table 6. Plasmids constructed in this study and corresponding polyketide products. 
Plasmid  Genes Products Ref. 
pJX120  pdmABCDGEHIKL 4 17 
pKN35  pdmABCDGEHIKLJ 4, 5 This work 
pKN92 pdmABCDGEHIKLW 4, 8 This work 
pKN93  pdmABCDGEHIKLN 4, 6 This work 
pKN89  pdmABCDGEHIKLNJ 4, 6 This work 
pKN90 pdmABCDGEHIKLJW 4, 5, 8, 9 This work 
pKN102 pdmABCDGEHIKLNW 4, 6, 8, 10 This work 
pKN87 pdmABCDGEHIKLJNW 4, 6, 5, 8, 9, 11 This work 
pKN50 pdmN n.a. This work 
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The products were extracted with ethyl acetate/methanol/acetic acid (89:10:1) and 
analyzed by LC-MS. As expected, S. coelicolor CH999/pKN35 (Figure 13, trace i) 
produced 4 as the major product and the hydroxylated analogue 5 as a minor metabolite 
(1.7 ± 0.2 mg L-1), which is consistent with our previous discovery.14 In contrast, S. 
coelicolor CH999/ pKN92 (Figure 13, trace ii) produced a different minor compound 8 
(1.4 ± 0.4 mg L-1) in addition to 4. This compound has a UV/Vis absorption spectrum 
similar to that of 4 (Figure 37), indicating that they share a similar structure. ESI-MS 
revealed that its molecular weight is 448 (Figure 36), 16 amu larger than 4, suggesting that 
it is a hydroxylated product of 4. As 5 and 8 have different retention times, it was proposed 
that the latter has a hydroxy group at a position other than C-5. We previously detected a 
similar compound produced by S. coelicolor CH999/pJX152 possessing the same set of 
genes, but it was not structurally characterized, due to the lack of sufficient amounts of 
pure compound.14 In this work, we scaled up the culture to 6 L and purified 6.0 mg of 8 for 
NMR analysis (Figure 38).  
The 13C NMR spectrum of 8 revealed that it has 24 carbons, confirming that it is a 
dodecaketide synthesized by the pradimicin biosynthetic enzymes (Figure 39). Compared 
to 4, which has a CH2 group at both C-5 and C-6, 8 has a single CH2 group but contains a 
new oxygenated CH group. This suggested that the hydroxy group was introduced at C-5 
or C-6. Because 5 was already identified as 5-hydroxy-G-2 A, 8 was deduced to be a C-6-
hydroxylated derivative of 4. Further 2D NMR analysis of 8 (Figure 14) revealed 1H–1H 
COSY correlation of the oxygenated CH signal to 5-CH2 (Figure 40) and its HMBC 
correlation to C-4a (Figure 41), thus confirming that 8 is 6-hydroxy-G-2A, which was 
named KN92 (Table 2). The proton and carbon signals were assigned and are presented in 
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Table 7 and Table 8, respectively. We then prepared the MTPA esters of 8 to determine 
the configuration of C-6. As shown in Figure 14, the ∆δ values revealed that C-6 has R 
configuration. Full structural characterization of 8 confirmed that PdmW was the dedicated 
C-6 hydroxylase in pradimicin biosynthesis. Using the same method, we also determined 
the absolute configuration at C-5 of 5 to be R (Figure 15), which was not determined 
previously. We also recorded the 19F NMR data of these Mosher esters, which supported 
the determination of the absolute configurations of 5 and 8 (Figure 35).20 Therefore, this 
work allowed the characterization of PdmW as the C-6 hydroxylase and the R configuration 
at C-5 in 5 and C-6 in 8, which are consistent with the reported absolute configurations at 
the same positions in final product 1. 
Figure 13. Synergistic actions of two CYP hydroxylases in pradimicin biosynthesis. (i) 
HPLC trace of S. coelicolor CH999/pKN35; (ii) HPLC trace of S. coelicolor 
CH999/pKN92; (iii) HPLC trace of S. coelicolor CH999/pKN90. These extracts were 
analyzed at 460 nm. 
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Table 7. The 1H NMR data (300MHz) of 8, 9 and 11 (in DMSO-d6,  in ppm, J in Hz). 
Position 8 9 11 
4 6.64 (1H, s) 6.89 (1H, s) 6.83 (1H, s) 
5 2.83-2.98 (2H, m) 4.50 (1H, d, J=3.0) 4.49 (1H, d, J=3.1) 
6 5.16 (1H, s) 5.09 (1H, d, J=2.1) 5.09 (1H, d, J=2.8) 
10 6.57 (1H, s) 6.64 (1H, d, J=2.4) 6.64 (1H, d, J=1.7) 
12 7.12 (1H, s) 7.19 (1H, d, J=2.4) 7.19 (1H, d, J=2.0) 
14 8.82 (1H, s) 8.93 (1H, s) 8.87 (1H, s) 
15 2.47 (1H, s) 2.57 (1H, s) 2.36 (1H, s) 
17   4.47 (1H, m) 
19   1.39 (1H, d, J=7.2) 
7-OH 12.47 (1H, s) 12.54 (1H, s) 12.54 (1H, s) 
9-OH 12.03 (1H, s) 12.13 (1H, s) 12.14 (1H, s) 
11-OH 11.46 (1H, brs) 11.42 (1H, s) 11.62 (1H, brs) 
16-NH   8.86 (1H, d, J=5.9) 
 
 
Table 8. The 13C NMR data (75MHz) of 8, 9 and 11 (in DMSO-d6,  in ppm). 
 
 
Position 8 9 11 Position 8 9 11 
1 162.3 160.8 153.1 11 165.7 165.9 165.8 
2 113.1 113.8 125.3 12 108.9 109.0 108.9 
3 143.1 144.3 137.8 12a 135.3 135.3 135.4 
4 123.4 119.6 124.3 13 181.4 181.9 181.7 
4a 141.9 143.3 140.1[a] 13a 131.3[a] 131.5 131.6[a] 
5 37.2 71.0 70.9 14 119.9 119.6 119.8 
6 56.9 62.1 62.4 14a 140.0 139.2 140.4[a] 
6a 131.5[a] 132.1 131.4[a] 14b 117.2 116.9 116.8 
7 158.5 160.2 160.0 15 23.7 23.3 19.4 
7a 113.2 114.3 113.4 16 173.9 174.2 167.5 
8 189.3 190.1 189.6 17   48.2 
8a 109.1 109.1 109.2 18   174.7 
9 164.5 164.5 164.5 19   16.5 
10 107.9 108.3 107.9     
[a] Assignment interchangeable. 
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Figure 14. Key 1H-1H COSY and HMBC correlations for 8, 9 and 11. 
3.4.2 Synergistic actions of two CYP hydroxylases in pradimicin biosynthesis 
As described above, PdmJ and PdmW were characterized as CYP hydroxylases that 
introduce a hydroxy group to C-5 and C-6 of the pradimicin structure, respectively. 
However, the yields of 5 and 8 were low, as shown in Figure 13, traces i and ii. The major 
metabolite in both S. coelicolor CH999/pKN35 and S. coelicolor CH999/pKN92 was still : 
4, the benzo[a]naphthacenequinone intermediate formed by the biosynthetic genes 
pdmABCDGHKL in pJX120. Apparently, these CYP enzymes when expressed 
individually were not efficient in converting 4 into the corresponding monohydroxylated 
products. To test whether these two CYP hydroxylases work collaboratively, plasmid 
pKN90 that contains pdmABCDGHKL and both pdmJ and pdmW was constructed. Co-
expression of these two hydroxylases in S. coelicolor CH999 resulted in the production of 
5, 8, and a new product 9 (18.7 ± 1.7 mg L-1; Figure 13, trace iii). Compound 9 had a shorter 
retention time (9.6 min) than 5 and 8 on a reversed-phase C18 HPLC column, suggesting 
that it is more polar than the other two compounds. The UV/Vis absorptions of 9 (Figure 
37) indicated that it is an analogue of 1. ESI-MS spectra of 9 showed the ion peaks, 
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including [M-H]- at m/z 462.9 and [M+H]+ at m/z 465.0, indicating that it has a molecular 
weight of 464 (Figure 36). This is 16 amu larger than 5 and 8, indicating that 9 is a 
dihydroxylated product (Figure 36).  
 
Figure 15. Determination of the absolute configurations of 5 and 8 using Mosher's 
method, Δ (S-R, in ppm) values in pyridine-d5. 
The 1H NMR spectrum of 9 exhibited 12 proton signals (Figure 42), including three 
hydroxy protons, four phenolic protons, two oxygenated CH protons, and a CH3 group 
(Table 7). The 13C NMR spectrum of 9 showed 24 carbons (Figure 43) including two 
carbonyl groups, one carboxyl group, 18 aromatic carbons, one methyl group, and two 
oxygenated CH groups (Table 8). The NMR data are very similar to those of 4, 5, and 8. 
The major difference is that 9 does not have any CH2 groups, suggesting that both C-5 and 
C-6 are hydroxylated. Unlike the monohydroxylated compounds 5 and 8, the 1H NMR 
signals for H-5 and H-6 were doublets at  = 4.50 and 5.09 ppm, respectively. The 13C 
NMR and DEPT spectra showed that the chemical shifts of C-5 and C-6 were  71.0 (CH) 
and 62.1 ppm (CH), respectively.  
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Figure 16. HPLC analysis of alanylation by PdmN. Biotransformation of 4 (i), 5 (ii), 8 
(iii), and 9 (iv) by S. coelicolor CH999/pKN50 at 460 nm. 
The 1H-1H COSY correlations between H-5 and H-6 (Figure 44), and the HMBC 
correlations (Figure 45) of H-4 to C-5 and H-6 to C-4a at  143.3, and H-5 to C-6a at 132.1 
ppm, confirmed that C-5 and C-6 were hydroxylated (Figure 14) . This was also supported 
by the 1H-1H ROESY correlations shown in Figure 34. Thus, 9 was characterized as 5,6-
dihydroxy-G-2A, which was named KN90 (Table 2), according to the name of the 
producing plasmid, pKN90. We previously functionally expressed PdmJ in E. coli, and the 
engineered strain converted 4 into the C-5-hydroxylated product 5 with low efficiency. The 
conversion rate was improved when glucose dehydrogenase was coexpressed to recycle 
the cofactors.18  
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Although both PdmJ and PdmW can catalyze the corresponding hydroxylations of 
4, the efficiencies of both individual reactions were low. However, these two CYP enzymes 
work collaboratively to efficiently generate a new pradimicin biosynthetic intermediate 9. 
A similar synergistic phenomenon with cyclases PdmK and PdmL was found in the 
formation of the pentangular structure of pradimicins, which require the presence of PdmH, 
a monooxygenase that oxidizes ring B into the quinone form, to close rings C–E.17 It is 
also known that KS and CLF in type II polyketide biosynthetic pathways form a 
heterodimer to promote chain length control. In the case of PdmJ and PdmW, either 
enzyme can work separately, but it is apparent that both enzymes work more efficiently 
when coexpressed. Therefore, it is proposed that these two CYPs form a complex to 
catalyze the dihydroxylation of the substrate. Our previous work on PdmJ revealed 
substrate inhibition of this enzyme in the in vitro reactions.18 The synergistic actions of 
PdmJ and PdmW are likely due to the prevention of substrate inhibition in pradimicin 
biosynthesis.  
3.4.3 Broad substrate specificity of PdmN 
Previously, PdmN was identified as an amino acid ligase that can accept D-alanine 
or D-serine to give different pradimicin analogues.14 The relaxed amino acid substrate 
specificity of PdmN makes it a useful biocatalyst to generate novel pradimicin analogues. 
Previous attempts to express PdmN in E. coli BL21(DE3) by using the expression vector 
pET28a failed because an insoluble form of the enzyme was generated,18 and similar results 
were obtained with other expression vectors such as pACYCDuet-1 and with different E. 
coli expression conditions. In the current work, PdmN expression in S. coelicolor CH999 
was attempted, as functional expression of PdmN and other biosynthetic enzymes was 
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successful to afford 6.14 Expression plasmid pKN50 was constructed by ligating pdmN 
(1863 bp) into the pRM5 vector (Table 6). The plasmid was introduced into S. coelicolor 
CH999, and the transformant was used to test alanylation of different substrates, including 
4, 5, 8, and 9. To confirm that this strain had functional PdmN, exogenously fed 4 was 
shown to be converted into its alanylated derivative 6 by cells of S. coelicolor 
CH999/pKN50 (Figure 16, trace i).  
3.4.4 Combinatorial biosynthesis of new pradimicin analogues 
We next made a series of plasmids to generate new pradimicin analogues through 
combinatorial biosynthesis, which was achieved by combining one, two or all of the three 
tailoring enzymes (PdmN, PdmJ and PdmW) with the early biosynthetic enzymes (Table 
6). All genes are transcribed from a single promoter/regulator actI/actII-ORF4. Ligation of 
pdmN into pJX120 yielded pKN93 (Table 6), which was introduced into S. coelicolor 
CH999. S. coelicolor CH999/pJX120, which produces 4 as the major product, was used as 
the control (Figure 17, trace i). LC-MS analysis of the culture of S. coelicolor 
CH999/pKN93 in R5 agar showed that 6 was produced in a high yield (31.9 ± 3.1 mg L-1), 
with 4 as the minor product (Figure 17, trace ii). When PdmJ was introduced into the 
system (pKN89), however, the same products as produced by S. coelicolor CH999/pKN93 
were obtained (Figure 17, trace iii). This result suggested that, although both PdmN and 
PdmJ can use 4 as the substrate for C-16 alanylation and C-5 hydroxylation, respectively, 
it is apparent that PdmN has higher affinity for the intermediate 4 than does PdmJ. 
Compound 6 was efficiently synthesized from 4 by PdmN. PdmJ cannot further 
hydroxylate 6 to yield the corresponding alanylated and C-5 hydroxylated product. 
Accordingly, 5 was not observed, due to the low efficiency of the C-5 hydroxylation. This 
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is consistent with the in vitro results from our previous work.18 In contrast, when pKN102 
harboring pdmABCDGHKLNW was expressed in S. coelicolor CH999, several products, 
including 4, 6, 8, and 10 (0.3 ± 0.1 mg L-1) were biosynthesized (Figure 17, trace iv). The 
UV/Vis spectrum of 10 suggested that it was a pradimicin analogue (Figure 37). ESI-MS 
of 10 showed the [M-H]- peak at m/z 518 (Figure 36), indicating that it has a molecular 
weight of 519, which is 71 amu larger than that of 8 (Figure 36). This suggested that 10 
(Table 2) is the alanylated derivative of 8 and the same as the biotransformation product of 
8 by PdmN (Figure 16, trace iii).  
Although the 13C NMR spectrum was not acquired, due to the lack of sufficient 
amounts of 10, the presence of the oxygenated H-6, as well as H-17 and CH3-19 from the 
D-alanine moiety, was confirmed by the proton signals at δ = 5.16 (s, 1H), 4.20 (s, 1H), 
and 1.27 ppm (s, 3H), respectively, in the 1H NMR of 10. Accordingly, the structure of 10 
was deduced to be 6-hydroxy-JX137a. Therefore, in addition to 4, which was formed by 
PdmABCDGHKL, 6 and 8 resulted from the individual tailoring actions catalyzed by 
PdmN and PdmJ, respectively, and 10 was generated by the actions of both enzymes. 
However, the overall efficiency was still low, and 4 was accumulated as the major 
metabolite. Apparently, coexpression of PdmJ or PdmW with PdmN and other early 
biosynthetic enzymes yielded no or small amounts of the expected hydroxylated and 
alanylated product (0.3 ± 0.1 mg L-1 of 10), suggesting that PdmN cannot efficiently work 
with either of the two CYP enzymes. As we found that PdmJ and PdmW work 
synergistically to generate the dihydroxylated product 9, we hypothesized that 
collaboration of PdmN with both CYP enzymes might be required to generate a new 
pradimicin analogue.  
63 
 
To this end, we coexpressed these three enzymes with the G-2A-forming enzymes 
by constructing a new expression plasmid, pKN87 (Table 6). Expression of this plasmid in 
S. coelicolor CH999 led to the production of a series of products, including 4, 6, 8, 9, and 
11, with 11 being the most predominant product (32.4 ± 2.2 mg L-1).  
 
Figure 17. Combinatorial biosynthesis of new pradimicin analogues. (i) HPLC trace of 
S. coelicolor CH999/pJX120; (ii) HPLC trace of S. coelicolor CH999/pKN93; (iii) 
HPLC trace of S. coelicolor CH999/pKN89; (iv) HPLC trace of S. coelicolor 
CH999/pKN102; (v) HPLC trace of S. coelicolor CH999/pKN87. These extracts were 
analyzed at 460 nm. 
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Compound 11 was identical to the PdmN-catalyzed biotransformation product of 9 
in S. coelicolor CH999 (Figure 16, trace iv). Compound 11 was isolated from a scaled-up 
culture as an orange solid. Its molecular weight was found to be 535, according to the ion 
peaks, including [M-H]- at m/z 534.0 (Figure 36) and [M+H]+ at m/z 536.1 in the ESI-MS 
spectra. It showed typical UV/Vis absorptions of pradimicins (Figure 37), thus suggesting 
that it is a pradimicin analogue. The 1H and 13C NMR (Figure 46 and Figure 47) spectra 
revealed that compared to 9, 11 has extra proton and carbon signals including one methyl, 
one carboxyl, one methine and one NH group, which belongs to a D-alanine moiety 
introduced by PdmN. In the HMBC spectrum (Figure 49), the correlations of NH at δ = 
8.86 (d, J=5.9, 1H) to C-16 at 167.5 and C-18 at 174.7, as well as H-19 at 1.39 ppm (d, J= 
7.2, 3H) to C-18 (Figure 14) confirmed that the amino acid was connected to C-16 to form 
an amide group (Figure 49). The 1H, 1H ROESY correlations also supported the connection. 
Therefore, 11 was characterized as an alanylated analogue of 9, which was named KN87 
(Table 2) (Figure 46 to Figure 49). Compound 11 was found to be a major product in the 
culture of S. coelicolor CH999/pKN87 (Figure 17, trace v). It represents an important 
intermediate in pradimicin biosynthesis that can be further decorated by late tailoring 
enzymes, such as methyltransferases, oxygenases, and glycosyltransferases, to form the 
final structure of 1.  
Structural analysis of 10 and 11 confirmed that they were the products from the 
PdmN-catalyzed alanylation of 8 and 9, respectively. It is apparent that all of the three 
studied tailoring enzymes (PdmJ, PdmW, and PdmN) can use 4 as a substrate. As shown 
in the HPLC traces of S. coelicolor CH999/pKN35 (Figure 13, trace i), S. coelicolor 
CH999/pKN92 (Figure 13, trace ii), and S. coelicolor CH999/pKN93 (Figure 17, trace ii), 
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PdmN can ligate the D-alanine moiety into 4 to form 6 efficiently, whereas PdmJ and 
PdmW are much less efficient in their corresponding hydroxylations. Different 
combinations of these tailoring enzymes generate various product profiles that provide 
important information about substrate specificity of these enzymes. Efficient production of 
11 further confirmed that synergistic actions of biosynthetic enzymes are important for the 
assembly of 1. Compounds 4–11 were tested for the antifungal activity against Candida 
albicans ATCC MYA-2876. However, none of these compounds showed inhibition of this 
fungus at the test concentrations (0.9–500 mg/mL). This is consistent with previous reports 
on the analogues of the aglycon pradimicinone, which further confirmed that the sugar 
moieties are essential for the biological activities of pradimicins.21, 22  
3.5 Conclusions  
Compound 1 is a promising lead compound for antiviral and antifungal therapeutics 
development. Combinatorial biosynthesis represents an effective approach to creating 
diverse analogues for drug development.23 In this work, PdmW was characterized as the 
C-6 hydroxylase, and PdmN was found to accept different amino acid acceptor substrates. 
Moreover, this work demonstrated synergistic actions of two tailoring CYP enzymes in 
pradimicin biosynthesis (Figure 18). Together with our previous discovery on the 
collaboration of two cyclases and a monooxygenase in the early biosynthetic steps of 1,17 
it can be concluded that the pradimicin biosynthetic enzymes have extensive synergistic 
actions and interactions during the biosynthetic process. Concerted actions of the PKS and 
three cyclases have also been reported in the resistomycin biosynthetic pathway to form 
the discoid ring structure.24 Thus, we propose that synergistic actions of biosynthetic 
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enzymes are a common approach for type II polyketide biosynthetic pathways that consists 
of a series of discrete enzymes to achieve the accuracy and overall efficiency of the product 
assembly lines. Understanding of the functions of individual enzymes and their synergistic 
actions will facilitate rational and efficient combinatorial biosynthesis of new molecules 
for bioactivity screening. 
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4 CHAPTER 4 
THREE ENZYMES INVOLVED IN THE N-METHYLATION AND 
INCORPORATION OF THE PRADIMICIN SUGAR MOIETIES3 
4.1 Abstract 
Pradimicins are antifungal and antiviral natural products from A. hibisca P157-2. 
The sugar moieties play a critical role in the biological activities of these compounds. There 
are two glycosyltransferase genes in the pradimicin biosynthetic gene cluster, pdmS and 
pdmQ, which are putatively responsible for the introduction of the sugar moieties during 
pradimicin biosynthesis. In this study, we disrupted these two genes using a double 
crossover approach. Disruption of pdmS led to the production of pradimicinone I, the 
aglycon of pradimicin A, which confirmed that PdmS is the O-glycosyltransferase 
responsible for the first glycosylation step and attaching the 4',6'-dideoxy-4'-amino-D-
galactose or 4',6'-dideoxy-4'-methylamino-D-galactose moiety to the 5-OH. Disruption 
of pdmQ led to the synthesis of pradimicin B, revealing that this enzyme is the second 
glycosyltransferase that introduces the D-xylose moiety to the 3′-OH of the first sugar. 
Insertion of an integrative plasmid before pdmO might have interfered with the dedicated 
promoter, yielding a mutant that produces pradimicin C as the major metabolite, which 
suggested that PdmO is the enzyme that specifically methylates the 4′-NH2 of the 4',6'-
dideoxy-4'-amino-D-galactose moiety. Functional characterization of these sugar-
                                                 
 
3 Co-authors: Zhang, S.; Anderson, T.; Takemoto, J. Y.; and Zhan, J. 
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decorating and -incorporating enzymes thus facilitates the understanding of the pradimicin 
biosynthetic pathway.1 
4.2 Introduction 
Pradimicins A–C (1–3) (Table 1) are aromatic polyketide natural products from the 
soil bacterium A. hibisca P157-2. Since their discovery in 1988, these molecules have been 
intensively studied. 1 is a promising lead compound due to its combined 
antifungal/antiviral properties. It was found to be active against a broad-spectrum of 
opportunistic and pathogenic fungi. This compound also interferes with the recognition of 
HIV-1 to its target cells. The mechanism of action of 1 emphasizes its lectin-like property 
in the presence of Ca2+ ions.2 The moieties of 1 form a primary cavity with C-14 and C-15 
from the benzo[α]naphthacenequinone and several hydroxyl groups of D-
mannopyranoside.3 Based on the intermolecular distance in the proposed model, it is 
believed that the free carboxyl group at C-18 of two molecules of 1 interacts with one Ca2+ 
ion.3 Another study on the anticandidal mode of action was done with the semisynthetic 
pradimicin derivative, BMY-28864.4 It was concluded that the sugar moieties of 
pradimicins, especially thomosamine or 4', 6'-dideoxy-4'-methylamino-D-galactose, were 
critical for sugar-recognition and involved in binding to the specific mannan. The 
pradimicin (pdm) biosynthetic gene cluster has previously been reported (NCBI accession 
number: EF151801.1). This reported gene cluster consists of 28 open reading frames.5 
Through combinatorial biosynthesis and heterologous expression, we have identified the 
enzymes that synthesize the pentangular intermediate G-2A, including PdmA, B, C, D, G, 
H, K, and L.6 Two cytochrome P450 enzymes, PdmJ and PdmW, were functionally 
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characterized as the dedicated hydroxylases that specifically introduce a hydroxyl group to 
C-5 and C-6, respectively.4 We have also identified PdmN as an amino acid ligase that 
introduces a D-alanine moiety at C-16. This enzyme was found to possess broad substrate 
and donor specificity.7, 8 Synergistic actions of tailoring enzymes in pradimicin 
biosynthesis commonly exit to ensure an efficient assembly process. In this work, we show 
the functional characterization of three late tailoring enzymes, including PdmS, PdmQ and 
PdmO, using a homologous gene recombination approach. PdmS and PdmQ were 
characterized as the GTs that successively introduce the 4',6'-dideoxy-4'-methylamino-D-
galactose/4',6'-dideoxy-4'-amino-D-galactose and D-xylose moieties to the structure, while 
PdmO is responsible for the N-methylation of 4',6'-dideoxy-4'-amino-D-galactose at 4'-
NH2. 
 
Figure 19. The structure of the pradimicin aglycon (12). 
As in the pradimicin family, many other important antibiotics such as erythromycin 
naturally contain deoxysugar moieties attached to the aglycon. Because these sugar 
moieties often play a critical role in the bioactivities of these natural products, it is of great 
interest to identify the GTs responsible for transferring these deoxysugars to the aglycons. 
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The pdm biosynthetic gene cluster contains two putative GT genes, pdmS and pdmQ. 
Sequence analysis indicated that they belong to a family of GTs that catalyzes the final 
stage of the biosynthesis of glycosylated natural products such as vancomycin and 
chloroeremomycin.  
4.3 Materials and Methods 
4.3.1 Primers and plasmid construction 
To understand the role of PdmS in pradimicin biosynthesis, we designed two sets 
of primers to inactivate this gene using a double crossover approach. A 1482-bp left arm 
and a 1404-bp right arm were cloned from the genome of A. hibisca P157-2. These two 
fragments were ligated to the thermal sensitive plasmid pKC1139 between HindIII and 
XbaI as well as XbaI and EcoRI, respectively, to yield a disruption plasmid pKN82. The 
primers used and plasmids constructed in this work are shown in Table 9 and Table 11, 
respectively. Using a similar double crossover approach, we constructed a pKC1139-
derived disruption plasmid pKN88 (Table 11) after the amplification of a 1224-bp left arm 
and a 1445-bp right arm.  
To determine the function of PdmO, we constructed an integrative plasmid pKN99 
(Table 11) in the pKC1139 vector and a 1.3-kb insert that contains the C-terminal portion 
of pdmO and N-terminal portion of pdmS (Figure 21). In addition, to confirm the double 
cross over and integration of the plasmid we constructed the primers-check specific for 
pdmS and pdmQ, primer 1 and 2 for pdmO (Table 9), and M13-47 and RV-M specific for 
the integrative vector pKC1139. 
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Table 9. Primers to clone the upstream and downstream region of each gene. 
Primer Sequence  
pdmS-KO-left arm-HindIII-F 5'-AAGCTTCCCGTCTCGGAGGTCAGC-3' 
pdmS-KO-left arm-XbaI-R 5'-TCTAGAGACGTAGAGCCGTTCCAGG-3' 
pdmS-KO-right arm-XbaI-F 5'-TCTAGATCCTGCACGTCCAGACCG-3' 
pdmS-KO-right arm-EcoRI-R 5'-GAATTCCCACCCAACCCCTAACCC-3' 
pdmS-check-F 5'-ATGGCGAACATCCTGATCAG-3' 
pdmS-check-R 5'-TCAGGCGATGACGGGACGGC-3' 
pdmQ-KO-left arm-HindIII-F 5'-AAGCTTCAGTCAGCAAGCACAGCAGG-3' 
pdmQ-KO-left arm-XbaI-R 5'-TCTAGACGTGGGATTCGGCAGCAT-3' 
pdmQ-KO-right arm-XbaI I-F 5'-TCTAGACGCCACATCGTCTGCTGC-3’ 
pdmQ-KO-right arm-EcoRI-R 5'-GAATTCCGTCCACCGTCACCTCCC-3' 
pdmQ-check-F 5'-ATGGCCGACATGCGGATCGT-3' 
pdmQ-check-R 5'-CTAAACCCCAAAAGTGAACC-3' 
pdmO-KO-HindIII-F 5'-AAGCTTCGTCCTGGAACGGCTCTA-3' 
pdmO-KO-XbaI-R 5'- TCTAGAAGGTCGAAGGTGCACATGTC-3' 
Primer 1 5'- CCGAGTACACCGACACGAT-3'  
M13-47 5'-GAGCGGATAACAATTTCACACAGG-3' 
RV-M 5'-CGCCAGGGTTTTCCCAGTCACGAC-3' 
Primer 2 5'-CTTGTCGATGAACCGTTCCG-3' 
 
 
4.3.2 Intergeneric conjugation  
E. coli ET12567 (pUZ8002) was transformed with pKN82, pKN88, and pKN99 
separately as the conjugation donor. 100 mL of each culture of E. coli 
ET12567(pUZ8002)/pKN82, pKN88, and pKN99 were grown separately in LB broth to 
an OD600 of 0.4-0.6 in the presence of 50 mg L-1 apramycin, 50 mg L-1 kanamycin, and 25 
mg L-1 chloramphenicol. The cells were then collected by centrifugation and washed twice 
with blank LB medium to remove the antibiotics, and then suspended in 0.1 mL of LB 
medium. A. hibisca spores were collected with 2-YT broth after growing for 15 days on 
YM medium at 30 oC. The A. hibisca spores were heat shocked at 50 C for 10 min. Serial 
dilutions of the germinated spore suspension were made and 100 µL of each dilution was 
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mixed with an equal volume of E. coli ET12567 (pUZ8002)/ pKN82, pKN88, or pKN99 
on MS plates (20 g L-1 D-mannitol, 20 g L-1 soya flower, 20 g L-1 glucose, and 20 g L-1 
agar), which were grown for 12 h at 30 oC. After incubation, the plates were overlaid with 
1 mL of sterile water containing 30 mg L-1 nalidixic acid and 50 mg L-1 apramycin, and 
incubated at 30 C until the exconjugants appeared. Exconjugants were visible after 4–5 
days and started producing spores in 8–10 days. Correct transformants of A. hibisca/pKN82, 
A. hibisca/pKN88, and A. hibisca/pKN99 were cultivated in YM broth (4 g L-1 D-glucose, 
4 g L-1 yeast extract, and 10 g L-1 malt extract) in the presence of 50 mg L-1 apramycin at 
28 C in a rotary shaker at 28 oC, and then cultivated on ISP4 plates with 50 mg L-1 
apramycin at 37 C for a period of 10 days to allow the plasmid to integrate into the genome.  
Conjugants of A. hibisca/pKN82 and A. hibisca/pKN88 were picked to YM broth 
without any antibiotics and incubated for 10 days at 28 C. The cultures were then spread 
onto ISP4 plates without antibiotics and grown for about 10 days at 28 C 9. The selection 
process for positive double crossover mutants was performed using a replica plate 
technique for colonies sensitive to 50 mg L-1 apramycin. Positive colonies were cultivated 
in YM broth in a rotary shaker at 28 C and were subjected to PCR screening using a set 
of pdmS and pdmQ specific primers (Table 9). The conjugants A. hibisca/pKN99 were 
selected on ISP4 medium with 50 µg mL-1 apramycin at 37 oC. Integration of pKN99 into 
the genome of A. hibisca was confirmed by PCR analysis using genome- and vector-
specific primers (Table 9). 
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4.3.3 Large scale culture and purification 
A seed culture of the mutant strain A. hibisca/pKN82 was cultivated in 50 mL of 
YM medium for 4 days at 28C in a rotary shaker at 250 RPM. The seed culture was 
inoculated to 500 mL YM broth and cultivated at the same conditions for 10 days. The 
culture of the double crossover mutant of A. hibisca/pKN82 was centrifuged and the 
supernatant was subjected to Diaion HP-20 resin column chromatography the column was 
eluted with 0%, 25%, 50%, 75%, and 100% aqueous methanol (v/v) to yield five fractions. 
HPLC analysis revealed that the 75% fraction contained the target peak. This fraction was 
further separated by a reverse-phase Agilent 1200 HPLC (Agilent Zorbax SB-C18 column, 
5 µm, 21.2 mm × 150 mm), eluted with 35% aqueous acetonitrile containing 0.1% formic 
acid, to yield 5.0 mg of 12. 
4.3.4 LC-MS and NMR analysis 
ESI-MS were acquired on an Agilent 6130 LC-MS HPLC (Agilent Zorbax SB-C18 
column, 5 µm, 21.2 mm × 150 mm). 1D and 2D NMR spectra were recorded on a JEOL 
ECX-300 instrument.  
4.4 Results and Discussion 
4.4.1 BLAST analysis 
BLAST analysis revealed that PdmS (GenBank accession number ABK58688) is a 
putative GT that contains 437 aa. Two proteins with the highest homology include two 
proposed GTs from Paenibacillus dendritiformis (GenBank accession number 
WP_006678995, 423 aa, 61% identity) and Bacillus cereus (GenBank accession number 
WP_002061747, 416 aa, 59% identity). However, none of these are functionally 
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characterized. We next sought to identify the O-GT that transfers the D-xylose moiety. 
PdmQ (GenBank accession number ABK58687) is the second putative GT in the pdm gene 
cluster that contains 435 aa. BLAST analysis showed that it is homologous to many GTs 
that are proposed to catalyze the transfer of sugar moieties from activated donor molecules 
to specific aglycons. The closest homologs found in GenBank are two GTs 
from Spirillospora albida (GenBank accession number WP_030163570, 414 aa, 61% 
identity) and Thermomonospora curvata (GenBank accession number WP_012855060, 
418 aa, 62% identity), respectively. Again, none of these homologs are identified.  
The structure of 1 contains a 4',6'-dideoxy-4'-methylamino-D-galactose moiety, 
while that of 3 does not have the N–CH3 group. A methyltransferase (MT) must be 
responsible for the methylation of this sugar moiety at the specific 4′-NH2 group. There are 
three putative MTs in the pdm gene cluster, including pdmF, pdmT and pdmO. BLAST 
analysis suggested that PdmF and PdmT are two O-MTs, while PdmO is a putative N-MT. 
PdmO (GenBank accession number ABM21743.1) contains 238 aa. It is homologous to a 
number of class I MTs that are dependent of S-Adenosyl-L-methionine (SAM) such as the 
sugar N,N-dimethyltransferases DesVI from Streptomyces venezuelae (67% similarity and 
53% identity)10 and TylM1 from Streptomyces fradiae (66% similarity and 52% 
identity).11 Both enzymes are involved in the biosynthesis of aminodeoxysugars. Thus, 
PdmO is a candidate enzyme that catalyzes the specific N-methylation of 4',6'-dideoxy-4'-
amino-D-galactose. 
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Table 10. 1H and 13C NMR data of 12 (recorded in d6-DMSO, 300 MHz). 
No. δH δC 
1 - 150.9 
2 - 127.1 
3 - 137.4 
4 7.04(s) 118.0 
4a - 140.9 
5 4.22(brs) 71.5 
6 4.22(brs) 72.4 
6a - 149.9 
7 8.07(s) 115.6 
7a - 131.2 
8 - 187.5 
8a - 110.1 
9 - 164.8 
10 6.87(brs) 106.9 
11 - 166.0 
12 7.21(brs) 107.6 
12a - 134.3 
13 - 185.2 
13a - 115.4 
14 - 156.8 
14a - 125.9 
14b - 113.7 
15 2.30(s) 19.2 
16 - 167.2 
17 4.37(m) 47.7 
18 - 174.2 
19 1.30(d, J=6.9Hz) 16.9 
11-OMe 3.89(s) 56.5 
9-OH 12.8(s) - 
16-NH 8.50(d, J=6.5Hz) - 
 
 
4.4.2 Plasmid construction 
List of plasmids constructed in this study. The PCR amplification of the left and 
right arm for disruption were sequenced; before the construction of their respective 
integration plasmid. 
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Table 11. Plasmids designed to disrupt the genes pdmS, pdmQ, and pdmO. 
Plasmid Description Reference 
pKN64 Left arm for pdmS disruption in pJET1.2 This work 
pKN63 Right arm for pdmS disruption in pJET1.2 This work 
pKN73 Left arm for pdmS disruption in pKC1139 This work 
pKN82 Both left and right arms for pdmS disruption in pKC1139 This work 
pKN70 Left arm for pdmQ disruption in pJET1.2 This work 
pKN71 Right arm for pdmQ disruption in pJET1.2 This work 
pKN81 Left arm for pdmQ disruption in pKC1139 This work 
pKN88 Both left and right arms for pdmQ disruption in pKC1139 This work 
pKN68 
A 1.3-kb fragment consisting of the C-terminal portion of pdmS 
and N-terminal portion of pdmO in pJET1.2 
This work 
pKN99 
A 1.3-kb fragment consisting of the C-terminal portion of pdmS 
and N-terminal portion of pdmO in pKC1139 
This work 
 
 
4.4.3 Confirmation of mutants by PCR and LC-MS analysis 
 A. hibisca/pKN82. As shown in Figure 22 (panel i), a 1.3-kb fragment of pdmS can 
be amplified from the genome of the wild type, while a disrupted gene pdmS with a length 
of 0.9 kb was cloned from the correct double crossover mutant. This confirmed that a 0.4-
bp fragment of pdmS has been successfully deleted from the genome of A. hibisca P157-2. 
The ∆PdmS mutant of A. hibisca P157-2 was then grown in YM medium for product 
analysis. The fermentation broth was centrifuged to separate the cells and supernatant, and 
the latter was injected into LC-MS for analysis. As shown in Figure 20, trace i, the wild 
type strain produces 1 as the major metabolite, with 2 and 3 as minor products depending 
on the culture time. In contrast, the ΔPdmS mutant did not produce 1-3. Instead, a new 
peak 12 (Table 2) was produced as a dominant product at 44 minutes (Figure 20, trace ii). 
The UV/Vis spectrum of 12 is similar to that of 1 (Figure 52), indicating that they have the 
same chromophore. Its molecular weight was found to be 549, according to the ion peaks 
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[M-H]- at m/z 548 and [M+H]+ at m/z 550. 12 in the ESI-MS spectra (Figure 53). This 
suggested that the strain A. hibisca/pKN82 has a ∆PdmS and produced the pradimicin 
aglycon that has no sugar moieties. 
 
Figure 20. HPLC analysis of the products synthesized by the mutant strains. A. hibisca. 
(i), A. hibisca ∆PdmS (ii), A. hibisca ∆PdmQ (iii), and A. hibisca/pKN99 single 
crossover mutant (iv). Samples were eluted with 20–35% acetonitrile-water (containing 
0.1% trifluoroacetic acid) over 40 minutes at 1 mL min-1. 
Figure 22 (panel ii), the intact pdmQ gene is 1.3 kb, while its mutant pdmQ is 1.0 
kb, confirming that a 0.3-kb fragment has been deleted from pdmQ. This mutant was grown 
in YM medium and the fermentation broth was analyzed by LC-MS. The double crossover 
mutant of A. hibisca/pKN88 did not produce 1 and 3, but a dominant product with the same 
retention time as 2 (Figure 20, trace iii). Further analysis of the UV/Vis absorption spectra 
(Figure 52) and MS (Figure 53) confirmed that this product is indeed pradimicin B (2). 
Thus, disruption of PdmQ led to the production of a major product with only the 4',6'-
20 30 40 50 min
ii)
iii)
iv)
i)
1
12
3
2
2
1
3
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dideoxy-4'-methylamino-D-galactose moiety, which confirmed the function of this enzyme 
as the O-GT responsible for transferring the second sugar moiety, D-xylose. Compound 12 
was observed as a minor product in this mutant, likely due to the incomplete glycosylation 
of this aglycon by PdmS. 
The fermentation broth of A. hibisca/pKN99 in YM medium supplemented with 50 
mg L-1 apramycin was analyzed by LC-MS. As shown in Figure 20 (trace iv), this strain 
produced a major product 3 that is slightly polar than 1. This compound has a UV/Vis 
spectrum (Figure 52) similar to that of 1, while ESI-MS revealed that its molecular weight 
is 826 (Figure 53), 14 mass units smaller than 1. It has the same retention time as that of 
pradimicin C (3). Thus, it can be concluded that A. hibisca/pKN99 produced 3 as the major 
product, with 1 as the minor product. Given the fact that 3 lacks the N–CH3, PdmO was 
deduced to be the dedicated N-MT in pradimicin biosynthesis that catalyzes the specific N-
methylation of the 4',6'-dideoxy-4'-amino-D-galactose moiety. Integration of pKN99 into 
the genome of A. hibisca did not disrupt pdmO (Figure 21).  
Consequently, the synthesis of 1 was still observed. However, insertion of a large 
fragment upstream of the intact pdmO may have influenced the function of the promoter 
that controls the expression of PdmO. This explains why 3 was generated as the major 
metabolite and is similar to the observations in our previous work on HerF in herboxidiene 
biosynthesis.12 Also 12 was a minor metabolite in this mutant, which might be caused by 
the incomplete glycosylation of the aglycon. 
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Figure 21. Disruption of pdmS, pdmQ and pdmO in A. hibisca. Double crossover and 
disruption gene strategies. 
4.4.4 Structure determination by NMR  
The NMR spectra of 12 were recorded. The 1H and 13C NMR spectra indicated that 
there are only signals of the pradimicin aglycon in 12, confirming that it is pradimicinone 
I. The 1H and 13C NMR signals were assigned based on the 2D NMR spectra including 
HSQC, HMBC and ROESY, and are shown in Table 10. These data were identical with 
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those of reported for pradimicinone I 13 Production of 1–3 by A. hibisca revealed that 
pradimicins with one or two sugar moieties are naturally synthesized, suggesting that the 
two sugar moieties are successively introduced. Identification of the product of the ∆PdmS 
mutant revealed the function of PdmS as the O-GT that is responsible for the introduction 
of the first sugar moiety, 4',6'-dideoxy-4'-amino-D-galactose or 4',6'-dideoxy-4'-
methylamino-D-galactose. 
 
Figure 22. Verification of the correct mutants by PCR. (i) Amplification of pdmS from 
the wild type (1.3 kb) and mutant (0.9 kb). M: marker; 1: wild type; 2: A. hibisca/pKN82 
double crossover mutant. (ii) Amplification of pdmQ from the wild type (1.2 kb) and 
mutant strain (1.0 kb). M: marker; 1: wild type; 2: A. hibisca/pKN88 double crossover 
mutant. (iii) Verification of the insertion of pKN99 into the genome of A. hibisca. M: 
marker; 1: primer 1/RV-M PCR product from the A. hibisca/pKN99 single crossover 
mutant; 2: primer 2/M13-47 PCR product from the A. hibisca/pKN99 single crossover 
mutant; 3: primer 1/primer 2 PCR product from the A. hibisca/pKN99 single crossover 
mutant; 4: primer 1/primer 2 PCR product from the wild type. 
4.5 Conclusions 
In summary, using a double crossover recombination approach, we disrupted two 
putative GT genes in the pradimicin biosynthetic gene cluster, leading to the production of 
pradimicin analogues with no or one sugar moiety. Based on the corresponding product of 
the mutants, PdmS and PdmQ were characterized as the GTs that are respectively 
responsible for the introduction of the first and second sugar moieties to the aglycon 12 
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(Figure 23). By inserting a large gene fragment into the genome of A. hibisca, we also 
found that PdmO methylates the amino group of the 4',6'-dideoxy-4'-amino-D-galactose 
moiety in pradimicin biosynthesis (Figure 23). Unveiling the roles of these GTs and the N-
MT further facilitates the understanding and rational engineering of the pradimicin 
biosynthetic pathway. 
 
Figure 23. Visual conclusion of the last steps in the synthesis of 1. 
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5 CHAPTER 5 
TWO PUTATIVE O-METHYLTRANSFERASES: PdmT and PdmF 
5.1 Abstract 
The sequence analysis of the gene cluster of pradimicin revealed two putative O-
methyltransferase genes, pdmT and pdmF. However, the final structures of the members in 
the pradimicin family have only one-methoxy group. A mutant strain derived by double 
cross-over recombination knockout of A. hibisca was isolated for accumulating a new 
pradimicin analogue KN85 (13) and lacking detectable synthesis of pradimicin A-C. This 
mutant lacks the specific O-methyltransferase activity given by PdmT. The activity of 
PdmT was reconstituted in vitro, when the putative coding gene pdmT was expressed and 
purified from a heterologous E. coli system. Incubation of PdmT with SAM and 13 yielded 
7-O-methyl-KN85 (14). Kinetic parameters of PdmT were obtained. These results 
established the function of PdmT as the 7-O-methyltransferase. Additional enzymes need 
to be discovered to understand how the methoxy group is removed to form the final 
structure of pradimicins A-C. Additionally, PdmF was revealed to be an O-
methyltransferase that methylates the hydroxyl group at C-11 of pradimicins A-C. By using 
combinatorial biosynthesis, a series of genes was co-expressed in a heterologous host. The 
function of PdmF was confirmed by LC-MS analysis of the products of the engineered 
strains as well as from the in vitro reaction of PdmF with KN87 (11), which generated a 
new methylated metabolite (17). 
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5.2 Introduction  
5.2.1 Methyltransferases in natural product biosynthesis 
PKSs and fatty acid synthases use condensation of simple carboxylic acid 
monomers common to synthesize their metabolic products.1 Besides the essential catalytic 
enzymes, several auxiliary functional (tailoring) enzymes add a variety of distinct chemical 
groups to the backbone residues of the secondary metabolites. This post-PKS modification 
results in increased structural diversity of small molecules, which radically affects the 
molecules’ biological activity, solubility, and binding properties. The tailoring enzymes 
vary in accordance with each antibiotic gene cluster; they include MTs, GTs, cytochromes 
P450, CYP, oxidases, amino acid ligases, or catalysts for other reactions.  
MTs are a large group of enzymes that methylate diverse substrates, including 
signaling and host defense compounds, pigments, prosthetic groups, cofactors, cell 
membrane, cell wall components, and xenobiotics.2 They can be divided into several 
subclasses based on their structural characteristics. Class I is the most common type MT, 
characterized by a Rossmann fold for binding the co-substrate SAM.3 Class II MTs contain 
a SET domain, 3, 4 and class III MTs are associated with the cell membrane.5 All natural 
product-MT (NPMT) structures elucidated belong either to class I3 or class III.4 MTs can 
also be grouped into different types according to different substrates in methyl transfer 
reactions. These types include protein MTs, DNA MTs or macromolecular MTs, MTs 
(NPMT), and non-SAM dependent MTs. More often, MTs are categorized based on the 
electron-rich methyl-accepting atom, including O (54% of EC subclass),6, 7, 8 N (23%),8, 9 
C (18%),6 S (3%),2, 6, 10, 11 or halide (2%),10, 12, 13 and some NPMTs methylate more than 
one type of acceptor atom.14 NPMTs can methylate on the polyketide aglycon or on the 
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sugars components, the sugar can be methylated either before or after transferring to the 
aglycon. 
An example of a post-PKS sugar modification is the reaction catalyzed by the N-
MT PdmO, in which the thomosamine (4'-amino-4',6'-dideoxy-D-galactose) is modified to 
finally synthesize 4',6'-dideoxy-4'-methylamino-D-galactose in pradimicin A and B.15 
Another example occurs during oleandomycin production, when OleY MT is involved in 
the biosynthesis of one of its sugars, L-oleandrose. L-olivose is first transferred to the 
oleandolide aglycone, which is then converted into L-oleandrose by the OleY MT.39 The 
biosynthesis of the anthracycline antitumor daunomycin has two MTs involved in its 
synthesis; dauC catalyzes the SAM-dependent methylation of aklanonic acid to aklanonic 
acid methyl ester. While dauK coded for carminomycin 4-O-methyltransferase, which 
catalyzes the transfer of a methyl group from SAM to the 4-O-position of carminomycin 
to form daunomycin.16 Also, the synthesis of tetracenomycin C requires three SAM-
dependent methylations by TcmN, TcmO, and TcmP. TcmN has a second function: it uses 
its N-terminal portion in the cyclization of a polyketide, while the C-terminal portion 
contains the methyltransferase activity.17 TcmP lacks the SAM binding motif and its amino 
acid sequence is different from other SAM-dependent enzymes.18 The temP gene contains 
codons infrequently used in Streptomyces spp., the codons TTA and TTT,19 positioned in 
the C-terminal part of the ORF, are not present in any of the other ORFs of the entire TCM 
C cluster.20 In the biosynthesis of herboxidine, HerF is the methyl transferase in the last 
step of the pathway.21 
SAM is the standard methyl donor for MTs; however, other methyl donors are seen 
in nature. The overall mechanism to transfer a methyl group is a SN2-like nucleophilic 
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attack where the methionine sulfur assists as the nucleophile that carries the methyl group 
to the substrate (Nu:). SAM is converted to S-adenosyl-L-homocysteine (SAH) through 
this reaction. The cleavage of the SAM-methyl bond and the release of the substrate-methyl 
bond (Nu-CH3) happen nearly simultaneously (Figure 24).  
NPMTs are attractive targets for protein engineering due to their variety of 
substrates and the broad substrate selectivity that some NPMTs have. However, more 
studies on the regeneration of SAM in a metabolic engineering context are required in order 
to engineer NPMTs.22, 23, 24 Regiospecific methylation is challenging, it often requires 
elaborated steps for the addition of protecting groups and does not always produce high 
yields.  
 
Figure 24. Reaction mode of SAM-dependant NPMTs. NPMTs use SAM as a methyl 
donor (dashed) for transfer to a methyl acceptor (Nu:). The methylated product forms 
(Nu-CH3) and S-adenosyl-L-homocysteine (SAH) is produced and it is a potent inhibitor 
of SAM-dependent MTs. 
The NPMTs in type II polyketide biosynthetic pathways vary in the number of 
amino acid residues, usually ranging from 200 to 500, corresponding to the molecular 
weight of 25-55 kDa; however, for modular PKS, methyltransferase (MT) domains have 
been described25 for PKS type I and the hybrid NRPS (non-ribosomal peptide 
synthetase)/type I PKS.26 Almost all NPMTs currently isolated share α-helices and β-
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strands alternating along their polypeptide chain. Homologous sequence studies of SAM-
dependent NPMTs have found conserved motifs among these proteins.27, 28, 29, 30 The 
regions associated with SAM binding are related to motifs I – VI.27, 31, 32  
Sequence analysis of the two MTs studied in this chapter has been conducted by 
alignment with MTs from the biosynthetic pathways of other angucyclic antibiotics such 
as rubromycin, griseorhodin, and fredericamycin. PdmT (340 aa) was proposed to be a MT 
based on the amino acid sequence homology to TcmO (339 aa) from S. glaucescens and 
GrhL (343 aa) from Streptomyces sp. JP95. The putative function of PdmF (342 aa) was 
likewise proposed due to its homology to TcmN (494 aa) from S. glaucescens and FdmN 
(353 aa) from S. griseus.33 This study established the functional characterization of PdmT 
and PdmF in the pradimicin biosynthetic pathway. 
5.3 Materials and Methods 
5.3.1  General  
ESI-MS spectra were acquired on an Agilent 6130 LC-MS HPLC (Agilent Zorbax 
SB-C18 column, 5 µm, 4.6 × 250 mm). 1D and 2D NMR spectra were recorded on a JEOL 
instrument (300 MHz). E. coli XL1-Blue (Agilent) was used as a host for general cloning 
and E. coli ET12567(pUZ8002) was used as a donor strain for intergeneric conjugation E. 
coli/Actinomadura.34 E. coli BL21 (DE3) and E. coli BL21 (DE3)-RIL were used as the 
protein expression hosts. All strains of E. coli were grown in LB medium at 250 rpm and 
37C in the presence of appropriate antibiotics (50 μg mL-1): ampicillin, kanamycin, or/and 
chloramphenicol. A. hibisca P157-2 strain was obtained from the American Type Culture 
Collection (ATCC 53557) and was grown in YM broth or YM agar.  
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The commercial vectors pJET1.2 (Fermentas) and pCR-Blunt (Life technologies) 
were used as the cloning vectors. The temperature sensitive E. coli-Streptomyces shuttle 
vector (Aprr) used was pKC1139.35 The vector pET28a(+) was used for protein expression 
under the T7 promoter. Isolation of plasmid DNA from E. coli was performed with a 
GeneJET™ Plasmid Miniprep Kit (Fermentas) by following the manufacturer’s 
instructions. Restriction enzymes and T4 DNA ligase were purchased from New England 
BioLabs. 
Table 12. Designed PCR primers for knockout and protein expression. 
Primer Sequence 
pdmT- left arm-HindIII-F 5'- AAGCTT CCCCG ACACC CTCAA CAT -3' 
pdmT - left arm-XbaI-R 5'- TCTAGA CGGCG ACTTCT TCAAC GAC -3' 
pdmT-right arm-XbaI-F 5'- TCTAGA CGGTG TAGGT GGGCT TGG -3' 
pdmT-right arm-EcoRI-R 5'- GAATTC GGTCT GGACG TGCAG GAAC -3' 
pdmT-NdeI-F 5'-AACATATG ACGGT GACCG GCACA CC-3' 
pdmT- EcoRI -R 5'-AAGAATTC TCAGC GCTTG CGCGC GATG-3' 
pdmF- left arm-HindIII-F 5'- AAGCTT GCGCA TGTTC CTCGA CTACG -3' 
pdmF - left arm-XbaI-R 5'- TCTAGA GTCGC GGTGG CTGTC GTC -3' 
pdmF-right arm-XbaI-F 5'- TCTAGA CTACC TGCTG AAAGC GATCC -3' 
pdmF-right arm- EcoRI -R 5'- GAATTC CCGAC CGAGT ACCAG ACCC -3' 
pdmF-NdeI-F 5'- AACATATG ATGACC GAACC GGAAG GAC -3' 
pdmF-EcoRI-R 5'- GAATTC TCAGA TGGGG CGGCA CTCCA -3' 
 
 
5.3.2  Primers and cloning 
To investigate the function of the putative O-methyltransferases, PdmT and PdmF, 
an approach to disrupt the genes by double-crossover homologous recombination was 
engineered. The primers were designed to clone the upstream and downstream part of each 
gene to knockout. Each pair of homologous fragment would then be ligated into the 
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HindIII/EcoRI sites of the thermo sensitive vector pKC1139 to constitute the disruption 
plasmids. Moreover, specific primers for cloning the gene fragments were designed and 
are shown in Table 12. 
5.3.3  Intergeneric conjugation approach 
The procedure to disrupt the genes pdmT and pdmF in A. hibisca through double 
crossover recombination34 was mentioned in detail in our previous publication.15  
5.3.4  Combinatorial biosynthesis approach for pdmF 
The plasmids in Table 13 were used for the co-expression of five combinatorial 
cassettes of genes previously constructed36, 37 in the expression vector pRM5 (tsr). The 
gene pdmF was site-specifically integrated into the genome of S. coelicolor using the 
integrative vector pSET152 (Aprr) (pJX156). Each pair of plasmids was introduced into 
the protoplast34 of S. coelicolor through PEG-mediated transformation34. After the 
regeneration of the protoplasts, the correct apramycin and thiostrepton resistant colonies 
were selected and picked to grow on R5 agar supplemented with 50 mg L-1 apramycin and 
50 mg L-1 thiostrepton for a period of 12-15 days at 28oC. Each co-transformed strain was 
separately extracted with ethyl acetate:methanol:acetic acid (89:10:1) and dried in vacuo. 
The extracts were resuspended in 100% DMSO and analyzed by LC-MS (Agilent Zorbax 
SB-C18 column, 5 µm, 4.6 × 250 mm eluted with a linear gradient method (10 to 90% 
acetonitrile in water containing 0.1% trifluoroacetic acid over 25 min).  
5.3.5 Protein expression and purification 
Methyltransferase PdmT. For the expression of PdmT the corresponding gene was 
cloned from the genome of A. hibisca, using the pair of primers (pdmF-NdeI-F and pdmF-
EcoRI-R) in Table 12 and ligated into the cloning vector pJET 1.2. After confirmation of 
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the correct amplification by DNA sequencing the gene pdmT was excised and ligated into 
the NdeI/EcoRI restriction sites of the expression vector pET28a(+) to yield the plasmid 
pKN122. The expression of pKN122 was performed by E. coli BL21 (DE3) and cultured 
on LB agar containing 50 μg mL-1 kanamycin at 37 C for 16 hours. 500 μL of an overnight 
culture of BL21 (DE3)/pKN122 in LB broth was inoculated into 500 mL of LB 
supplemented with 50 μg mL-1 kanamycin and cultivated at 37 C in a rotary shaker at 250 
RPM. When the OD600 reached 0.4 - 0.6 (in about 4 hours) the culture was induced with 
0.1 mM IPTG and expressed at 18 C for 16 hours. The N-His6-tagged PdmT was purified 
by Ni-NTA chromatography and fractions collected were analyzed by SDS-PAGE. Protein 
quantification was determined with the Coomassie (Bradford) Protein Assay Kit from 
Thermo Scientific.  
 Methyltransferase PdmF. The gene pdmF was amplified from the genomic DNA 
of A. hibisca using the primers in Table 12 and cloned into the integrative pSET152 vector 
to yield the plasmid pJX156. DNA sequencing of the PCR product was performed to 
confirm correct amplification of the target gene. The gene pdmF was excised form pJX156 
and ligated into the NdeI/EcoRI restriction sites of the vector pET28a(+) to yield the 
plasmid pKN1.  
pKN1 was chemically transformed into the expression system E. coli BL21 (DE3)-
RIL and cultured on LB agar containing 50 μg mL-1 kanamycin and 25 μg mL-1 
chloramphenicol at 37 C for 16 hours. 500 μL of an overnight culture of BL21 (DE3)-
RIL/pKN1 in LB broth was inoculated into 50 mL of LB supplemented with 50 μg mL-1 
kanamycin and 25 μg mL-1 chloramphenicol and cultivated at 37 C in a rotary shaker at 
250 RPM. When the OD600 reached 0.4 - 0.6 the culture was induced with 0.2 mM IPTG 
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and expressed at 28 C for 16 hours. The N-His6-tagged PdmF was purified by Ni-NTA 
chromatography and fractions collected were analyzed by SDS-PAGE. Protein 
quantification was determined with the Coomassie (Bradford) Protein Assay Kit from 
Thermo Scientific.  
Table 13. Plasmids used for combinatorial biosynthesis approach for PdmF. 
Plasmid pairs Genes Products 
pJX12037 + pJX156 pdmABCDGHKL + F 4 
pKN9336 + pJX156 pdmABCDGHKLN + F 4, 6 
pKN3536 + pJX156 pdmABCDGHKLJ + F 4, 5, 15 
pKN9236 + pJX156 pdmABCDGHKLW + F 4, 8, 16 
pKN8736 + pJX156 pdmABCDGHKLJNW + F 4, 6, 9, 11, 17 
 
 
5.3.6  Kinetics 
In vitro reactions of PdmT. The enzyme PdmT was reacted with KN85 (13) (Table 
2), the accumulated intermediate in the pdmT mutant strain A. hibisca/pKN85. A standard 
in vitro reaction contained 75 mM Tris-HCl buffer (pH 7.5), 2 mM SAM, 0.05 mM of 
substrate (13), and 10.4 µM PdmT in a total volume of 100 μL. The reactions were 
quenched by heating inactivation of the enzyme at 90C for 5 min. To obtain the kinetic 
parameters, different concentrations of the substrates (ranging from 0.025 to 0.8 mM) were 
used. After centrifugation (15,000 rpm for 10 min) of the quenched reactions the 
supernatants were analyzed by LC-MS (Agilent Zorbax SB-C18 column, 5 µm, 4.6 × 250 
mm) eluted with a linear gradient method (30 to 40% acetonitrile in water containing 0.1% 
trifluoroacetic acid over 40 min).  
 In vitro reaction of PdmF. The enzyme PdmF was reacted with KN87 (11). 
Reactions contained 100 mM Tris-HCl buffer (pH 7.5), 1.22 mM SAM, 3 μM PdmF, and 
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0.05 mM substrate 11. Reactions were started by the addition of PdmF at 30 °C. After 2 h, 
the 100 μL reaction mixtures were stopped by adding 50 μL of methanol, which were then 
vortexed and centrifuged at 15,000 rpm for 10 min. The control was performed with boiled 
PdmF. The supernatants were analyzed by LC-MS (Agilent Zorbax SB-C18 column, 5 µm, 
4.6 × 250 mm) eluted with a linear gradient method (10 to 60% acetonitrile in water 
containing 0.1% trifluoroacetic acid over 25 min).  
5.3.7 Compound purification and structure determination by NMR 
 Compound KN85 (13). The culture seed of A. hibisca/pKN85 was grown in 50 mL 
of YM broth, in a 250 RPM rotary shaker at 28 C for 4 days. 10 mL of the culture seed of 
A. hibisca/pKN85 was inoculated to 500 mL of YM broth and cultivated for 15 days at 28 
C in a rotary shaker at 250 RPM. The A. hibisca/pKN85 culture was centrifuged at 4,000 
RPM for 8 minutes to separate the supernatant from the cell debris. The supernatant was 
then loaded onto an adsorbent Diaion HP-20 resin in an open column. The loaded column 
was washed with 4 volumes of deionized water, to remove the broth media and free 
molecules, and eluted with 25%, 50%, 75%, and 100% aqueous methanol (v/v) to yield 
five fractions. Each fraction was analyzed by HPLC. The fraction that contained the purest 
13 was dried in vacuo and dissolved in [d6] DMSO for further 1H NMR analysis in a JEOL 
ECX-300 instrument. 
 Compound 7-O-methyl-KN85 (14). The compound 14 (Table 2) was directly 
purified by HPLC (Agilent Zorbax SB-C18 column, 5 µm, 4.6 × 250 mm) from the in vitro 
reactions of PdmT/KN85 with constant method (30% acetonitrile in water containing 0.1% 
trifluoroacetic acid). 14 was dried in vacuo and dissolved in DMSO-d6 for further 1H NMR 
analysis on a JEOL ECX-300 instrument. 
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5.4 Results and Discussions 
To confirm the function of PdmT and PdmF, the upstream and downstream regions 
of pdmT and pdmF were cloned with the right and left arm primers engineered in Table 12. 
Each PCR product was ligated into the cloning vector pJET 1.2 for further DNA 
sequencing to confirm correct amplification (Table 14). Each sequenced result was then 
aligned with its homologous sequence using the DNAssist Software Version 2.0. After 
confirmation of their correct amplification, the left and right arms were excised and 
subsequently ligated into pKC1139 between the HindIII/XbaI and Xbal/EcoRI sites, 
respectively. The partial and final disruption plasmids are listed in Table 14. The genes 
pdmT and pdmF were ligated into the expression vector pET28a(+) to yield the final 
plasmids pKN122 and pKN1, respectively (Table 14). 
Table 14. Plasmids for double cross over recombination and protein expression. 
Plasmid Arms/Genes Vector Reference 
pKN61 Upstream of pdmT pJET1.2 This work 
pKN62 Downstream of pdmT pJET1.2 This work 
pKN76 Upstream of pdmT pKC1139 This work 
pKN85 Upstream & downstream of pdmT pKC1139 This work 
pKN117 Mutant pdmT pJET1.2 This work 
pKN118 pdmT pJET1.2 This work 
pKN122 pdmT pET28a(+) This work 
pKN65 Upstream of pdmF pJET1.2 This work 
pKN66 Downstream of pdmF pJET1.2 This work 
pKN77 Upstream of pdmF pKC1139 This work 
pKN80 Upstream & downstream of pdmF pKC1139 This work 
pJX156 pmdF pSET152 This work 
pKN1 pdmF pET28a(+) This work 
 
 
The plasmids pKN85 and pKN80 were separately introduced into wild type A. 
hibisca by intergeneric conjugation through E. coli ET12567.34 The generated apramycin-
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resistant strains A. hibisca/pKN85 and A. hibisca/pKN80 appeared after 4 days of culture 
on MS agar at 28oC. For each strain, after plasmid-integration into the genomic DNA at 37 
C and double crossover recombination at 28 oC, the correct mutant phenotype was 
apramycin sensitive. The mutant strain A. hibisca/pKN85 was successfully obtained after 
several LC/MS analysis of the extract of potential mutant cultures. The mutant A. 
hibisca/pKN85 did not produce 1 but a less polar metabolite with maximum UV/Vis 
absorptions spectrum (240, 290, and 510 nm) (Figure 26 B, trace ii) that are different from 
those of 1 (230, 300, 460 nm) (Figure 26 B, trace i). This new metabolite, KN85 (13) 
(Figure 26 A, trace ii), has a molecular weight of 565, 275 amu smaller than 1. The 1H 
NMR spectra of 13 was recorded. It was determined that 13 has the same structure as the 
previously reported pradimicinone II (PMN II)38 (Figure 25 A) (Table 2). The proton 
signals were assigned based on the 1D and 2D NMR spectra and are shown in Figure 25 A 
(Table 15). 
 
 
Figure 25. Structure determination of compounds 13 and 14 by NMR. (A) The HMBC and 
ROESY correlation of 13. (B) Structure of 14. 
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Figure 26. LC/MS chromatograms and absorbance of compounds 1, 13, and 14. (Ai) 
Wild type A. hibisca culture presenting the production of 1 and (Bi) its characteristic 
UV/Vis spectrum (230, 300, 460 nm). (Aii) Mutant type A. hibisca/pKN85 showing its 
major product 13 and its (Bii) unique UV/Vis spectrum (240, 290, and 510 nm). (Aiii) 
HPLC profile for the in vitro conversion of 13 to 14 by PdmT, (Biii) typical UV/Vis 
spectrum of 14 (240, 290, and 475 nm). 
Identification of the product of the ∆pdmT mutant indicated the function of PdmT 
as the O-MT that is responsible for the methylation of the hydroxyl group at C-7. To 
confirm the deletion of the gene pdmT, the genotype of the mutant A. hibisca/pKN85 was 
analysed by PCR of the gene pdmT and compared to the amplification of the same gene 
from the wild type A. hibisca using the primers pdmT-NdeI-F/pdmT-EcoRI-R (Table 12) 
The PCR product obtained from the mutant strain, ∆ pdmT, was 386-bp shorter (Figure 27 
B, line 1) than pdmT amplified from the wild type strain (1017-bp) (Figure 27 B, line 2). 
The amplification of ∆pdmT was ligated into the pJET 1.2 vector to yield the plasmid 
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pKN117. Sequencing of the plasmid and its alignment with the pdmT sequence from NCBI 
(Accession number EF151801.1) confirmed that A. hibisca/pKN85 lacked a portion of the 
gene pdmT.  
 
Figure 27. Construction and verification of the ∆pdmT mutant strain. (A) Design of the 
plasmid for double crossover knockout of pdmT. (B) Line 1: Amplification of the gene 
pdmT from the mutant strain A. hibisca/KN85 (631 bp); line 2: Amplification of the gene 
pdmT from A. hibisca (1017 bp); C: Negative control; M: marker. 
To further understand the function of PdmT, the gene pdmT was expressed (37.1 
KDa) in the soluble form with the induction of 0.1 mM IPTG at 16 C in a rotary shaker at 
250 RPM. The N-His6-tagged protein was purified by Ni-NTA chromatography at 4 C 
Disruption
plasmid
Genome of
the wild type
Genome of
the mutant
pKN85
pdmT pdmSpdmU
1017 bp
631 bp
Left
arm
Right
arm
pdmT pdmSpdmU
A 
B 
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with a yield of 9.46 mg/L (Figure 28). To investigate its function, PdmT was reacted 
with 13 at 30 C. As shown in Figure 26 A, trace iii, the LC-MS results showed that all the 
substrate was converted to a more polar compound that has a different UV/Vis absorption 
spectrum (240, 290, 475 nm) and a molecular weight of 14 amu larger than 13 (Figure 26A, 
ii). These results strongly suggested the methylation of 13, while the position of 
methylation was unknown. The product, 14, was purified and subjected to 1H NMR for the 
determination of its structure (Table 15) (Figure 50) (Figure 51). Unexpectedly, we 
uncovered that the hydroxyl group at C-7 was methylated by PdmT (Figure 25 B). 13 can 
be efficiently converted to 14 by PdmT through O-methylation, confirming that this 
enzyme is a dedicated O-methyltransferase (Figure 29). We also obtained the kinetic 
parameters of PdmT, kcat: 27.7 min-1, KM: 6.8 mM, kcat/KM : 4.1 min-1mM-1.  
Figure 28. SDS-PAGE analysis of the expression and purification of PdmT. M: protein 
ladder, 1: soluble fraction, 2: insoluble fraction, 3: percolation, 4: elution with buffer A, 
5: elution with buffer A and 10 mM imidazole 6: elution with buffer A and 25 mM 
imidazole, 7: Elution with 250 mM imidazole. 
Thus, PdmT has been characterized as an O-methyltransferase involved in the 
biosynthesis of pradimicins. But because the final structures of pradimicins do not have 
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this methoxy group at C-7, we propose that 14 is an intermediate for further de-
methoxylation by other enzymes found in the gene cluster of pradimicin. 
 
Figure 29. Proposed reaction catalyzed by PdmT. 
Figure 30. SDS-PAGE analysis of the expression and purification of PdmF. M: protein 
ladder, 1: soluble fraction, 2: insoluble fraction, 3: percolation, 4: elution with buffer A, 
5: elution with buffer A containing 10 mM imidazole 6: elution with buffer A containing 
25 mM imidazole, 7: elution with buffer A containing 250 mM imidazole. 
 
The mutant strain A. hibisca/pKN80 underwent the same steps as the mutant strain 
A. hibisca/pKN85. However, we failed to obtain a ∆pdmF mutant strain. We then took an 
alternative approach to study the function of PdmF. By using a combinatorial biosynthesis 
approach, the gene pdmF was co-expressed with five different cassettes of genes that 
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synthesize the backbone structure of pradimicins (Table 13). The products were analyzed 
by LC/MS. The strains that produced any pradimicin intermediates without a hydroxyl 
group at C-5 or C-6 (4 and 6) did not yield any 11-O-methylated products. 
 
Figure 31. LC/MS analysis of new pradimicin analogues obtained by combinatorial 
biosynthesis. (i) Extract of strain S. coelicolor/pJX120 + pJX156. (ii) Extract of strain 
S. coelicolor/pKN93 + pJX156. (iii) Extract of strain S. coelicolor/pKN35 + pJX156. 
(iv) Extract of strain S. coelicolor/pKN92 + pJX156. (v) Extract of strain S. 
coelicolor/pKN87 + pJX156. 
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Table 15. The NMR data of KN85 (13) and 7-O-methyl-KN85 (14) (recorded in DMSO-
d6, 300 MHz). 
Position δH KN85 δC KN85 δH 7-O-methyl-KN85 
1 - 154.3 - 
2 - 128.0 - 
3 - 137.3 - 
3-CH3 - - 2.26 (3H, s) 
4 6.73 (s) 123.2 6.46 (1H, s) 
4a - 139.9 - 
5 4.46 (1H, brs) 71.2 4.32 (1H, brs) 
6 5.06 (1H, brs) 62.9 4.94 (1H, brs) 
6a - 136.9 - 
7 - 155.2 - 
7-OH 13.03 (s) - - 
7-OCH3 - - 3.78 (3H, s) 
7a - 113.2 - 
8 - 187.8 - 
8a - 110.2 - 
9 - 164.1 - 
9 12.34 (s) - - 
10 6.73 (1H, brs) 106.1 6.68 (1H, brs) 
11 - 166.0 - 
11-OCH3 3.91 (3H, s) 56.3 3.87 (3H, s) 
12 7.27 (1H, brs) 106.8 7.06 (1H, brs) 
12a - 136.6 - 
13 - 183.5 - 
13a - 111.2 - 
14 - 153.9 - 
14a - 136.7 - 
14b - 116.5 - 
15 2.30 (3H, s) 18.9 - 
16 - 167.5 - 
16-NH 8.49 (1H, d, 
J=6.2) 
- 8.79 (1H, brs) 
17 4.34-4.42 (1H, m) 47.8 4.35 (1H, m) 
17-CH3 - - 1.21 (3H, brs) 
18 - 174.2 - 
19 1.35(3H, d, J=7.2) 17.1 - 
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The expression of PdmF (37.01 KDa) in the soluble form was achieved with the 
induction of 0.2 mM IPTG at 25 C in a rotary shaker at 250 RPM. The N-His6 tagged 
protein was purified by Ni-NTA chromatography at 4 C with a yield of 26.39 mg L-1 
(Figure 30). To investigate the function of this putative methyltransferase, PdmF was 
reacted with 11 at 30 oC. As shown in Figure 32, trace i, the LCMS results showed that 
about 40% of the substrate 11 (MW 535) was converted to a less polar compound 17 (MW 
549) (Figure 33C). Compound 17 has a similar UV/Vis absorption spectrum to 11 and 14 
amu larger than 11. The methylation product 17 strongly suggested that PdmF is an O-
methyltransferase, also this result matches the result found in the combinatorial 
biosynthesis experiments (Figure 31, trace vi) where 11 is modified by PdmF in vivo to a 
compound with the same molecular weight (549), same UV/Vis absorption and same 
retention time as 17 (Figure 33).  
 
Figure 32. LC/MS analysis of PdmF in vitro reaction. (i) Methylation of 11 into 17. (ii) 
Standard of 11. HPLC conditions: 5 to 90% acetonitrile in water containing 0.1% 
trifluoroacetic acid over 30 min (Agilent Eclipse Plus-C18 column, 5 µm, 4.6 × 250 
mm). 
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Figure 33. Proposed methyl transfer reactions from SAM by PdmF. 
5.5 Conclusions 
Our results revealed that PdmT is an O-methyltransferase that uses SAM as a 
methyl donor. The ∆pdmT strain produced the metabolite 13, which in turn was used as 
substrate for in vitro reactions with PdmT. As expected, PdmT methylated 13 at C-7 to 
form 14. On the other hand, PdmF was revealed to be the enzyme that reacted with the 
hydroxyl group at C-11 to form the methoxy group found in the final structures of 
pradimicins.  
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We failed to obtain the ∆pdmF strain; however, we tested the substrate specificity 
by co-expressing pdmF with different sets of pradimicin biosynthetic genes in S. coelicolor. 
Our results showed that new methylated metabolites were synthesized when PdmF was 
expressed in the system and only the intermediates that were mono- or dihydroxylated at 
position C-5 and/or C-6 accepted the methyl group. Additionally, the result from the in 
vitro reaction of PdmF and the intermediate 11 yielded a methylated compound, 17, with 
the same characteristics as the molecule found in our first approach when 11 and PdmF 
were synthesized in vivo. Although the structure of 17 has not been determined by NMR 
spectroscopy, we are certain that PdmF is responsible for the methylation at C-11 in the 
synthesis of pradimicins. These results allowed us to characterize PdmT and PdmF as 
SAM-dependent O-methyltransferases. 
5.6 Acknowledgements 
This work was supported by the National Institute of Allergy and Infectious 
Diseases (R15AI089347).  
5.7 References 
1. Liou, G. F.; Khosla, C. Curr. Opin. Chem. Biol. 2003, 7, 279. 
2. Liscombe, D. K.; Louie, G. V.; Noel, J. P. Nat. Prod. Rep. 2012, 29, 1238. 
3. Schubert, H. L.; Blumenthal, R. M.; Cheng, X. Trends Biochem. Sci. 2003, 28, 329. 
4. Martin, J. L.; McMillan, F. M. Curr. Opin. Struct. Biol. 2002, 12, 783. 
5. Katz, J. E.; Dlakić, M.; Clarke, S. Mol. Cell. Proteomics 2003, 2, 525. 
6. Wlodarski, T.; Kutner, J.; Towpik, J.; Knizewski, L.; Rychlewski, L.; Kudlicki, A.; 
Rowicka, M.; Dziembowski, A.; Ginalski, K. PLoS One 2011, 6, e23168. 
106 
7. Barakat, A.; Choi, A.; Yassin, N. B. M.; Park, J. S.; Sun, Z.; Carlson, J. E. Gene 
2011, 479, 37. 
8. Lissina, E.; Young, B.; Urbanus, M. L.; Guan, X. L.; Lowenson, J.; Hoon, S.; 
Baryshnikova, A.; Riezman, I.; Michaut, M.; Riezman, H. PLoS Genet. 2011, 7, 
e1002332. 
9. Lee, S. G.; Kim, Y.; Alpert, T. D.; Nagata, A.; Jez, J. M. J. Biol. Chem. 2012, 287, 
1426. 
10. Coiner, H.; Schröder, G.; Wehinger, E.; Liu, C.-J.; Noel, J. P.; Schwab, W.; 
Schröder, J. Plant J. 2006, 46, 193. 
11. Nagatoshi, Y.; Nakamura, T. J. Biol. Chem. 2009, 284, 19301. 
12. Lomax, C.; Liu, W.-J.; Wu, L.; Xue, K.; Xiong, J.; Zhou, J.; McGrath, S. P.; Meharg, 
A. A.; Miller, A. J.; Zhao, F.-J. New Phytol. 2012, 193, 665. 
13. Peng, Y.; Feng, Q.; Wilk, D.; Adjei, A. A.; Salavaggione, O. E.; Weinshilboum, R. 
M.; Yee, V. C. Biochemistry 2008, 47, 6216. 
14. Schmidberger, J. W.; James, A. B.; Edwards, R.; Naismith, J. H.; O'Hagan, D. 
Angew. Chem. 2010, 49, 3646. 
15. Napan, K. L.; Zhang, S.; Anderson, T.; Takemoto, J. Y.; Zhan, J. Bioorg. Med. 
Chem. Lett. 2015, 25, 1288. 
16. Dickens, M. L.; Ye, J.; Strohl, W. R. J. Bacteriol. 1995, 177, 536. 
17. Shen, B.; Hutchinson, C. R. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6600. 
18. Decker, H.; Hutchinson, C. R. J. Bacteriol. 1993, 175, 3887. 
19. Wright, F.; Bibb, M. J. Gene 1992, 113, 55. 
20. Decker, H.; Motamedi, H.; Hutchinson, C. R. J. Bacteriol. 1993, 175, 3876. 
21. Yu, D.; Xu, F.; Zhang, S.; Shao, L.; Wang, S.; Zhan, J. Bioorg. Med. Chem. Lett. 
2013, 23, 5667. 
22. Akey, D. L.; Li, S.; Konwerski, J. R.; Confer, L. A.; Bernard, S. M.; Anzai, Y.; 
Kato, F.; Sherman, D. H.; Smith, J. L. J. Mol. Biol. 2011, 413, 438. 
23. Shi, R.; Lamb, S. S.; Zakeri, B.; Proteau, A.; Cui, Q.; Sulea, T.; Matte, A.; Wright, 
G. D.; Cygler, M. Chem. Biol. 2009, 16, 401. 
24. Cooke, H. A.; Guenther, E. L.; Luo, Y.; Shen, B.; Bruner, S. D. Biochemistry 2009, 
48, 9590. 
107 
25. Auclair, K.; Kennedy, J.; Hutchinson, C. R.; Vederas, J. C. Bioorg. Med. Chem. 
Lett. 2001, 11, 1527. 
26. Du, L.; Sánchez, C.; Shen, B. Metab. Eng. 2001, 3, 78. 
27. Kozbial, P. Z.; Mushegian, A. R. BMC Struct. Biol. 2005, 5, 19. 
28. Kagan, R. M.; Clarke, S. Biochemistry 1995, 34, 10794. 
29. Ingrosso, D.; Fowler, A. V.; Bleibaum, J.; Clarke, S. J. Biol. Chem. 1989, 264, 
20131. 
30. Schluckebier, G.; O'Gara, M.; Saenger, W.; Cheng, X. J. Mol. Biol. 1995, 247, 16. 
31. Pósfai, J.; Bhagwat, A. S.; Pósfai, G.; Roberts, R. J. Nucleic Acids Res. 1989, 17, 
2421. 
32. Jansson, A.; Koskiniemi, H.; Erola, A.; Wang, J.; Mäntsälä, P.; Schneider, G.; 
Niemi, J. J. Biol. Chem. 2005, 280, 3636. 
33. Kim, B. C.; Lee, J. M.; Ahn, J. S.; Kim, B. S. J. Microbiol. Biotechnol. 2007, 17, 
830. 
34. Kieser, T.; Bibb, M. J.; Buttner, M. J.; Chater, K. F.; Hopwood, D. A. Practical 
Streptomyces Genetics; John Innes Foundation, 2000. 
35. Bierman, M.; Logan, R.; O'Brien, K.; Seno, E. T.; Nagaraja Rao, R.; Schoner, B. E. 
Gene 1992, 116, 43. 
36. Napan, K.; Zhang, S.; Morgan, W.; Anderson, T.; Takemoto, J. Y.; Zhan, J. 
ChemBioChem 2014, 15, 2289. 
37. Zhan, J.; Qiao, K.; Tang, Y. ChemBioChem 2009, 10, 1447. 
38. Furumai, T.; Kakinuma, S.; Yamamoto, H.; Komiyama, N.; Suzuki, K.; Saitoh, K.; 
Oki, T. J. Antibiot. 1993, 46, 412. 
39.  Rodríguez, L.; Rodríguez, D.; Olano, C.; Braña, A. F.; Méndez, C.; Salas, J. A. J. 
Bacteriol. 2001, 183, 5358. 
 
 
 
6 CHAPTER 6 
CONCLUSIONS AND RECOMMENDED FUTURE RESEACH 
6.1 Conclusions  
To summarize our findings, the reconstruction of the late steps of the pradimicin 
biosynthetic pathway was possible through the interaction of genetic concepts and 
engineering strategies. Eight enzymes that modify the core structure of pradimicins have 
been studied in this work, including cytochrome P450 hydroxylases (PdmJ and PdmW), 
amino acid ligase (PdmN), O- and N-methyltransferases (PdmF, PdmT, and PdmO), and 
O-glycosyltransferases (PdmS and PdmQ). Our findings functionally characterized and 
described the interactions of the mentioned enzymes, biosynthesized pradimicin precursors, 
while explaining the biosynthetic pathway of the antifungal and antiviral pradimicins. 
The enzymes PdmJ and PdmW were characterized as cytochrome P450 
hydroxylases that catalyze the incorporation of two hydroxyl groups at C-5 and C-6, 
respectively. Our in vitro studies revealed that PdmJ hydroxylates C-5 in 4 to form 5. The 
PdmJ enzyme has narrow substrate specificity and substrate inhibition was detected for the 
first time in type II polyketide pathways, as well as competitive inhibition by 6. The in vivo 
studies were performed in E. coli BL21(DE3) that expressed both PdmJ and GDH. The 
bioconversion of 4 to 5 was achieved in a higher yield by feeding substrate 4 to the induced 
fermentation broth of the E. coli strain. Moreover, this reaction was done in 2 days, rather 
than 8 days that is required for S. coelicolor CH999/pJX134 to produce 5. The 
bioconversion approach by E. coli BL21(DE3)/pKN29 strain can be used to obtain 5 as a 
starting molecule for further modifications to generate novel pradimicin analogues. 
Additionally, PdmW was confirmed to be the cytochrome P450 hydroxylase responsible 
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for the hydroxyl group at C-6 of 4. It was demonstrated that the co-expression of PdmJ and 
PdmW significantly improved the hydroxylation steps. Thus, synergistic actions of the two 
tailoring cytochrome P450 enzymes; as well as interactions with PdmN in pradimicin 
biosynthesis were stablished. We believe that synergistic actions of biosynthetic enzymes 
are common in type II polyketide biosynthetic pathways. PdmN is an amino acid ligase 
that accepts a variety of substrates including 4, 8, and 9 and ligates a D-alanine moiety to 
the C-16 carboxyl group. In addition, the enzymes PdmS and PdmQ were characterized as 
the O-glycosyltransferases responsible for the introduction of the first and second sugar 
moieties to the aglycon of pradimicin (12). Besides, we confirmed that PdmO is the N-
methyltransferase that adds a methyl group to the amino group of the 4',6'-dideoxy-4'-
amino-D-galactose moiety in pradimicins. PdmT and PdmF were characterized as O-
methyltransferase enzymes that use SAM as a methyl donor. In vitro studies revealed that 
PdmT is responsible for the methylation of the hydroxyl group at C-7, which needs further 
enzymatic removal to form the aglycon of pradimicins. Additionally, PdmF was found to 
be the enzyme that reacted with the hydroxyl group at C-11 to form the methoxy group in 
the final structures of pradimicins. 
All our results together provide useful information for understanding and 
engineering the late steps in the biosynthetic pathway of pradimicins. New pradimicin 
analogues may be further generated for better drug candidates by rationally manipulating 
this pathway.  
6.2  Recommended Future Research  
Future studies needs to focus on the removal of the methoxy group at C-7. Because 
demethoxylation reactions are not common in natural product biosynthetic pathways, it 
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will be valuable to discover the enzyme that demethoxylates C-7. Since collaboration and 
synergy of enzymes have been observed in the pathway of pradimicins, it will not be a 
surprise that this demethylation is performed by two or more enzymes working together. 
There are a few remaining putative genes in the gene cluster that have not been studied yet, 
which may be further investigated for the enzymes involved in the C-7 demethoxylation.  
Additionally, by analyzing the mechanism of action of pradimicins and the pool of 
pradimicin precursors generated in this study, we believe that 12 and 13 might be good 
candidates for further modifications of their structure due to the presence of D-alanine, the 
hydroxyl group at C-14, the estimated production yield, and the easy extraction and 
purification. The fact that these two precursors lack the sugar moiety, directs glycosylation 
to C-5 or C-6. Since PdmS and PdmQ are classified now as O-GTs, structural analysis of 
these enzymes might help in the modification of their binding site to make them accept 
other sugar molecules and thus get modified pradimicins. Likewise, structural analysis for 
the other enzymes characterized in this studied may reveal important data about the 
substrate binding and catalytic sites, especially the enzymes with broad substrate 
specificity.  
From a different perspective, these molecules are endowed with pigmentation. It is 
possible that they could be modified to work as natural dyes, similar to λ-actinorhodin, a 
natural dye from another soil bacterium, Streptomyces coelicolor.  
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APPENDIX B. 
Data of compound 10 (KN102): 1H-NMR data (DMSO-d6, δ in ppm, J in Hz): 9.02(1H,s, 
H-14), 7.12(1H, s, H-12), 6.61(1H, s, H-4), 6.45(1H, s, H-10), 5.22(1H, brs, H-6), 4.20(1H, 
s, H-17), 2.93-3.02 (1H, m, H-5a), 2.72-2.80(1H, m, H-5b), 2.23(3H, s, H-15), 1.27(3H, s, 
H-19); ESI-MS: m/z 518.2[M-H]-. 
 
Figure 34. Key 1H-1H ROESY correlations for 9 and 11. 
 
 
 
Figure 35. Determination of the absolute configurations of 5 and 8. 19F NMR of Mosher’s 
method. F (ppm) values in pyridine-d5 are shown. 
KN87 (11) KN90 (9) 
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Figure 36. ESI-MS (-) spectrum of compounds 4-11. 
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Figure 37. UV/Vis spectrum of compounds 4-11. 
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Figure 38. 1H-NMR spectrum of compound 8. 
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Figure 39. 13C-NMR spectrum of compound 8. 
145 
 
Figure 40. 1H-1H COSY of compound 8. 
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Figure 41. HMBC of compound 8. 
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Figure 42. 1H-NMR spectrum of compound 9. 
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Figure 43. 13C-NMR spectrum of compound 9. 
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Figure 44. 1H-1H COSY of compound 9. 
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Figure 45. HMBC of compound 9. 
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Figure 46. 1H-NMR spectrum of compound 11. 
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Figure 47. 13C-NMR spectrum of compound 11. 
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Figure 48. 1H-1H COSY of compound 11. 
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Figure 49. HMBC of compound 11. 
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Figure 50. 1H-NMR spectrum of compound 14. 
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Figure 51. 1H-1H COSY of compound 14. 
 
  
APPENDIX C. 
LC/MS analysis of 1-3 and 12 
Figure 52. UV/Vis spectrum of 1, 2, 3, and 12. 
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Figure 53. ESI-MS spectrum of 1, 2, 3, and 12.VITA 
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